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Abstract
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and
survival. Melanoma and squamous cell carcinoma (SCC) are high-risk skin cancers, which have the potential to metastasise
and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised, with potential to infiltrate and damage
surrounding tissue. Anxiety around missing early cases needs to be balanced against inappropriate referral and unnecessary
excision of benign lesions. Optical coherence tomography (OCT) is a microscopic imaging technique, which magnifies the
surface of a skin lesion using near-infrared light. Used in conjunction with clinical or dermoscopic examination of suspected
skin cancer, or both, OCT may offer additional diagnostic information compared to other technologies.
Objectives
To determine the diagnostic accuracy of OCT for the detection of cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants, basal cell carcinoma (BCC), or cutaneous squamous cell carcinoma (cSCC) in adults.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; EMBASE; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
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Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies evaluating OCT in adults with lesions suspicious for invasive melanoma and atypical intraepidermal melanocytic
variants, BCC or cSCC, compared with a reference standard of histological confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). Our unit of analysis was lesions. Where possible, we estimated summary sensitivities and
specificities using the bivariate hierarchical model.
Main results
Five studies including 529 cutaneous lesions (273 malignant lesions) were included, providing nine datasets for OCT, two for
visual inspection alone, and two for visual inspection plus dermoscopy. Studies were of moderate to poor quality using data
driven thresholds for test positivity and giving poor accounts of reference standard interpretation and blinding. Studies may
not be representative of populations eligible for OCT in practice, for example due to high disease prevalence in study
populations, and may not reflect how OCT is used in practice, for example by using previously acquired OCT images.
It is not possible to make summary statements regarding accuracy of detection of melanoma or of cSCC because of the
paucity of studies, small sample sizes, and for melanoma differences in the OCT technologies used (high-definition versus
conventional resolution OCT), and differences in the degree of testing performed prior to OCT (i.e. visual inspection alone or
visual inspection plus dermoscopy).
Pooled data from two studies using conventional swept-source OCT alongside visual inspection and dermoscopy for the
detection of BCC estimated the sensitivity and specificity of OCT as 95% (95% CI: 91, 97%) and 77% (95% CI: 69, 83%),
respectively.
When applied to a hypothetical population of 1000 lesions at the mean observed BCC prevalence of 60%, OCT would miss
31 BCCs (91 fewer than would be missed by visual inspection alone and 53 fewer than would be missed by visual inspection
and dermoscopy), and OCT would lead to 93 false positive results for BCC (a reduction in unnecessary excisions of 159
compared to using visual inspection alone and of 87 compared to visual inspection and dermoscopy).
Authors' conclusions
Insufficient data are available on the use of OCT for the detection of melanoma or cSCC. Initial data suggests conventional
OCT may have a role for the diagnosis of BCC in clinically challenging lesions, our meta-analysis showing a higher sensitivity
and higher specificity when compared to visual inspection and dermoscopy. However the small number of studies and
varying methodological quality means implications to guide practice cannot currently be drawn.
Appropriately designed prospective comparative studies are required, given the paucity of data comparing OCT with
dermoscopy and indeed other similar diagnostic aids such as reflectance confocal microscopy.
Plain language summary
What is the diagnostic accuracy of optical coherence tomography (OCT), an imaging test, for the detection of
skin cancer in adults?
Why is improving the diagnosis of skin cancer important?
There are a number of different types of skin cancer. Melanoma is one of the most dangerous forms, and it is important that it
is recognised early so that it can be removed. If it is not recognised (also known as a false negative test result), treatment
can be delayed, and this risks the melanoma spreading to other organs in the body, which may lead to eventual death.
Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are usually localised (i.e. limited to a certain
part of the body) skin cancers, although cSCC can spread to other parts of the body and BCC can cause disfigurement if not
recognised early. Diagnosing a skin cancer when it is not actually present (a false positive result) may result in unnecessary
surgery and other investigations and can cause stress and anxiety to the patient. Making the correct diagnosis is important,
and mistaking one skin cancer for another can lead to the wrong treatment being used or lead to a delay in effective
treatment.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate optical coherence tomography (OCT) is for diagnosing skin
cancer. Researchers in Cochrane included five studies to answer this question. Two studies were concerned with the
diagnosis of melanoma and three with the diagnosis of BCC.
What was studied in the review?
A number of tools are available to skin cancer specialists which allow a more detailed examination of the skin compared to
examination by the naked eye alone. Currently, a dermatoscope is used by most skin cancer specialists, which magnifies the
skin lesion using a bright light source. OCT magnifies the surface of a skin lesion to the level of that seen using a microscope
using near-infrared light. It is quick to perform but is more expensive compared to dermoscopy and requires specialist
training. Researchers examined how useful OCT is to help diagnose skin cancers when used after visual inspection or visual
inspection and dermoscopy.
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What are the main results of the review?
The review included five studies: two studies with a total of 97 participants with 133 skin lesions suspected of being
melanoma, and three studies with a total of 314 participants with 396 lesions suspected of being BCC of which one (50
lesions) also analysed cSCCs (9 lesions).
The studies investigating the accuracy of OCT for diagnosing melanoma were small and too different from each other to
allow a reliable estimate of the accuracy of OCT for melanoma to be made. Similarly, only one small, low-quality study
investigated the accuracy of OCT for diagnosing cSCC.
For identifying BCC, two studies show the effects of skin specialists using OCT after visual inspection alone, or visual
inspection with dermoscopic examination. These two studies indicate that in theory, if OCT were to be used in a group of
1000 people with skin lesions that are particularly difficult to diagnose, of whom 600 (60%) actually have BCC, then:
- An estimated 662 people will have an OCT result confirming that a BCC is present and of these 93 (14%) will not actually
have a BCC (false positive result)
- Of the 338 people with an OCT result indicating that no BCC is present, 31 (9%) will in fact actually have a BCC (false
negative result)
Compared to making a diagnosis of BCC using visual inspection and dermoscopy, the addition of OCT in this group would
reduce the number of false positive results by 87 (thus reducing unnecessary surgical procedures) and would miss 53 fewer
BCCs.
How reliable are the results of the studies of this review?
In all included studies, the diagnosis of skin cancer was made by lesion biopsy (OCT/dermoscopy positive) (a biopsy
involves taking a sample of body cells and examining them under a microscope), and the absence of skin cancer was
confirmed by biopsy (OCT/dermoscopy negative)*. This is likely to have been a reliable method for deciding whether patients
really had skin cancer. However, the small number of studies included in this review, and variability between them, reduces
the reliability of findings. Included studies also had important limitations, in particular study participants were from more
restricted groups than would be eligible for an OCT scan in practice (for example all studies included people with skin lesions
that had already been selected for surgical removal), while the way in which OCT was used may not reflect real life
situations.
Who do the results of this review apply to?
Studies were conducted in Europe and the US only. Mean age (reported in only two studies) was 46 years for melanoma and
63 years for BCC. The percentage of people with a final diagnosis of melanoma was 23% and 27% (in two studies), ranged
from 58% to 61% for BCC (three studies), and was 18% for cSCC (one study). For the diagnosis of BCC, the results apply to
people with 'pink' and non-pigmented skin lesions that the clinician considers particularly difficult to diagnose by the naked
eye alone.
What are the implications of this review?
Not enough research has been done regarding the use of OCT in detecting skin cancers. The results of this review suggest
that OCT might help to diagnose BCC when it is difficult to distinguish it from benign skin lesions, but it is not yet clear
whether it can adequately distinguish between BCC, cSCC and melanoma skin cancers. More studies are needed comparing
OCT to dermoscopy and to other microscopic techniques (such as reflectance confocal microscopy) in well-described groups
of people with suspicious skin lesions.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy or clinical follow-up were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers conducted for the National Institute for Health Research (NIHR) Cochrane
Systematic Reviews Programme. Appendix 1 shows the content and structure of the programme. Table 1 provides a
glossary of terms used.
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma has the highest skin cancer mortality (Cancer Research UK 2017
), however the commonest skin cancers in Caucasian populations are those arising from keratinocyte cells: basal cell
carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010). In 2003, the World
Health Organization estimated that between two and three million ‘non-melanoma’ skin cancers (of which BCC and
cSCC are estimated to account for around 80% and 16% of cases respectively) and 132,000 melanoma skin cancers
occur globally each year (WHO 2003).
In this diagnostic test accuracy review, the target conditions of interest are: (a) melanoma, (b) basal cell carcinoma, and (c)
cutaneous squamous cell carcinoma. We will also examine accuracy for the target condition of (d) any skin cancer or other
lesion requiring excision, including melanoma or atypical intraepidermal melanocytic variants, keratinocyte skin cancer, any
other skin cancer, and severely dysplastic melanocytic lesions.
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Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin.
Melanoma can occur in any organ that contains melanocytes, including mucosal surfaces, the back of the eye, and lining
around the spinal cord and brain, but most commonly arises in the skin. Cutaneous melanoma refers to any skin lesion with
malignant melanocytes present in the dermis, and includes superficial spreading, nodular, acral lentiginous, and lentigo
maligna melanoma variants (see Figure 1) (SIGN 2017). Melanoma in situ refers to malignant melanocytes that are
contained within the epidermis and have not yet invaded the dermis, but are at risk of progression to melanoma if
left untreated. Lentigo maligna, a subtype of melanoma-in-situ in chronically sun-damaged skin, denotes another
form of proliferation of abnormal melanocytes. Melanoma in situ and lentigo maligna are both atypical
intraepidermal melanocytic variants. All forms of melanoma in situ can progress to invasive melanoma if its growth
breaches the dermo-epidermal junction during a vertical growth phase, although malignant transformation is both
lower and slower for lentigo maligna than for melanoma in situ (Kasprzak 2015). Melanoma in situ and lentigo maligna
are both atypical intraepidermal melanocytic variants. Melanoma is one of the most dangerous forms of skin cancer,
with the potential to metastasise to other parts of the body via the lymphatic system and blood stream. It accounts for
only a small percentage of skin cancer cases but is responsible for up to 75% of skin cancer deaths (Boring 1994; Cancer
Research UK 2017). The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann
2013; Ferlay 2015), with an estimated 55,000 deaths (Ferlay 2015). The highest incidence is observed in Australia with
11,405 new cases of melanoma of the skin (ACIM 2014) and in New Zealand with 2,341 registered cases (HPA and MelNet
NZ 2014) in 2010. For 2014 in the USA, the predicted incidence was 73,870 per annum and the predicted number of
deaths 9,940 (Siegel 2015). The highest rates in Europe are seen in north-western Europe and the Scandinavian
countries, with highest incidence reported in Switzerland of 25.8 per 100,000 in 2012. Rates in the UK have trebled
from 4.6 and 6.0 per 100,000 in men and women, respectively in England in 1990, to 18.6 and 19.6 per 100,000 in
2012 (EUCAN 2012). In the UK, melanoma has one of the fastest rising incidence rates of any cancer, and has had the
biggest projected increase in incidence between 2007 and 2030 (Mistry 2011). In the decade leading up to 2013, age
standardised incidence increased by 46%, with 14,500 new cases in 2013 and 2459 deaths in 2014 (Cancer Research UK
2017). Rates are higher in women than in men; however, the rate of incidence in men is increasing faster than in
women (Arnold 2014).The rising incidence in melanoma is thought to be primarily related to an increase in recreational
sun exposure and tanning bed use and an increasingly ageing population with higher lifetime recreational ultraviolet
(UV) exposure, in conjunction with possible earlier detection (Linos 2009; Belbasis 2016). Putative risk factors
including eye and hair colour, skin type and density of freckles, history of melanoma, sunburn, and presence of
particular lesion types are reviewed in detail elsewhere (Belbasis 2016).
A database of over 40,000 US patients from 1998 onwards which assisted the development of the 8th American
Joint Committee on Cancer (AJCC) Staging System indicated a five-year survival of 97% to 99% for stage I
melanoma, dropping to between 32% and 93% in stage III disease depending on tumour thickness, the
presence of ulceration and number of involved nodes (Gershenwald 2017). While these are substantial increases relative
to survival in 1975 (Cho 2014), increasing incidence between 1975 and 2010 means that mortality rates have reportedly
remained static. This observation coupled with increasing incidence of localised disease, suggests that improvements in
survival may be due to earlier detection and heightened vigilance (Cho 2014). Targeted therapies for stage IV
melanoma (e.g. BRAF inhibitors) have improved survival expectation and immunotherapies are evolving such that
long term survival is being documented (Pasquali 2018).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the follicular bulge and interfollicular
epidermis (Grachtchouk 2011). Growth is usually localised, but it can infiltrate and damage surrounding tissue, which if
left untreated can cause considerable destruction and disfigurement, particularly when located on the face (Figure 2
). The four main types of BCC are superficial, nodular, morphoeic or infiltrative, and pigmented. Lesions typically
present as slow-growing asymptomatic papules, plaques, or nodules which may bleed or form ulcers that do not
heal (Firnhaber 2012). People with a BCC often present themselves to health care professionals with a non-healing
lesion rather than specific symptoms such as pain. Many lesions are diagnosed incidentally (Gordon 2013).
BCC most commonly occurs on sun-exposed areas of the head and neck (McCormack 1997), and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin types I and II (Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer history; immunosuppression; arsenic
exposure; and genetic predisposition, such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich 2004).
Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over the last
four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been attributed to
an ageing population, changes in the distribution of known risk factors, particularly ultraviolet radiation, and
improved detection due to the increased awareness amongst both practitioners and the general population (Verkouteren
2017). Hoorens 2016 points to evidence for a gradual increase in the size of BCCs over time, with delays in diagnosis
ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low-risk BCCs are
nodular lesions occurring in people older than 24 years old who are not immunosuppressed and do not have Gorlin's
syndrome. Furthermore, lesions should be located below the clavicle; should be small (< 1 cm) with clinically well-
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defined margins; not recurrent following incomplete excision or other treatment; and not in awkward or highly visible
locations (NICE 2010). Superficial BCCs are also typically low risk and may be amenable to medical treatments
such as cryotherapy, photodynamic therapy or topical immunomodulatory therapy e.g. 5% Imiquimod cream (Kelleners-
Smeets 2017). Assigning BCCs as low or high risk influences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on the H-area of the face (Lear 2014), can arise from long-standing
untreated lesions, or from a recurrence of aggressive basal cell carcinoma after primary treatment (Lear 2012).
Very rarely, BCC may metastasise to regional and distant sites resulting in death; this is particularly true for large
neglected lesions in those who are immunosuppressed, or those with Gorlin syndrome (McCusker 2014). Rates of
metastasis are reported at 0.0028% to 0.55% with very poor survival rates (Lo 1991). . It is recognised that
basosquamous carcinoma (more like a high risk cSCC in behaviour and not considered a true BCC) is likely to have
accounted for many cases of apparent metastases of BCC hence the spuriously high reported incidence in some
studies of up to 0.55% which is not seen in clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis or its appendages. cSCC typically presents with an
ulcer or firm (indurated) papule, plaque, or nodule (Griffin 2016) often with an adherent crust (Madan 2010) (Figure 2).
cSCC can arise in the absence of a precursor lesion, or may develop from pre-existing actinic keratosis or Bowen's
disease (considered by some to be cSCC in situ); the estimated annual risk of progression being <1% to 20% for newly
arising lesions (Alam 2001) and 5% for pre-existing lesions (Kao 1986). It remains locally invasive for a variable
length of time, but has the potential to spread to the regional lymph nodes or via the bloodstream to distant sites,
especially in immunosuppressed individuals (Lansbury 2010). High risk lesions are those arising on the lip or ear,
recurrent cSCC, lesions arising on non-exposed sites, within scars or chronic ulcers, tumours more than 20mm in
diameter and those with a histological depth of invasion exceeding 4mm, and poor differentiation status on
pathological examination (Motley 2009). Perineural nerve invasion of PNI of at least >0.1 mm in diameter is a further
documented risk factor for high risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF mutation inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; 
Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients,
cSCC is the most common form of skin cancer; the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic
recurrence of cSCC at five years is estimated at 8% and 5% respectively. The five-year survival rate of
metastatic cSCC of the head and neck is around 60% (Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is wide local excision of the lesion, to remove both the
tumour and any malignant cells that might have spread into the surrounding skin (Sladden 2009; Marsden 2010; NICE
2015a; Garbe 2016; SIGN 2017). Recommended surgical margins vary according to tumour thickness (Garbe 2016)
and stage of disease at presentation (NICE 2015a). Following histological confirmation of diagnosis, the lesion is
staged according to the American Joint Committee on Cancer (AJCC) Staging System to guide treatment (Balch 2009).
Stage 0 refers to melanoma in situ; stages I to II indicate localised melanoma; stage III occurs where there is regional
metastasis; and stage IV indicates distant metastasis (Balch 2009). The main prognostic indicators can be divided into
histological and clinical factors. Histologically, Breslow thickness is the single most important predictor of survival, as it
is a quantitative measure of tumour invasion which correlates with the propensity for metastatic spread (Balch 2001).
Microscopic ulceration, mitotic rate, microscopic satellites, regression, lymphovascular invasion, and nodular (rapidly
growing) or amelanotic (lacking in melanin pigment) subtypes (Moreau 2013; Shaikh 2012) are also associated
with worse prognosis. Independent of tumour thickness, prognosis is worse in: older people, males, those with
recurrent lesions, and in those with distant lymph node involvement (micro or macroscopic) and/or metastatic
disease at the time of primary presentation. There is debate regarding the prognostic effect from primary lesion
site, with some evidence suggesting a worse prognosis for truncal lesions or those on the scalp or neck (Zemelman 2014).
Treatment for BCC and cSCC can be different to melanoma, in that there are a range of primary treatment options that
include surgery, other destructive techniques such as cryotherapy or electrodesiccation and topical chemotherapy. A
Cochrane systematic review of 27 randomised controlled trials (RCTs) of interventions for BCC found very little good
quality evidence for any of the interventions used (Bath-Hextall 2007b). Complete surgical excision of primary BCC
has a reported five-year recurrence rate of <2% (Griffiths 2005; Walker 2006), leading to significantly fewer recurrences
than treatment with radiotherapy (Bath-Hextall 2007b). After apparent clear histopathological margins (serial vertical
sections) after standard excision biopsy with 4mm surgical peripheral margins taken there is a 5-year reported
recurrence rate of around 4% (Drucker 2017). Mohs micrographic surgery, whereby horizontal sections of the excised
specimen are microscopically examined intraoperatively, and re-excision is undertaken until the margins are tumour-
free, can be considered for high-risk lesions such as on the centre of the face where standard wider excision margins
might lead to incomplete excision or considerable functional and/or cosmetic impairment (Bath-Hextall 2007b; Lansbury
2010; Motley 2009; Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall 2007b) found a single trial comparing
Mohs micrographic surgery with a 3mm surgical margin excision in BCC (Motley 2009), showing non-significantly lower
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recurrence at 10 years with Mohs micrographic surgery (4.4% compared to 12.2% after surgical excision, P = 0.10) (van
Loo 2014).
Bath-Hextall 2007b The main treatments for high risk BCC are wide local excision, Mohs micrographic surgery and
radiotherapy. For low risk or superficial subtypes of BCC, or for small and/or multiple BCCs at low risk sites (Marsden 2010
), destructive techniques other than excisional surgery may be used (e.g. electrodesiccation and curettage or
cryotherapy (Alam 2001; Bath-Hextall 2007b)). Alternatively, non-surgical (or non-destructive) treatments may be
considered (Bath-Hextall 2007b; Drew 2017; Kim 2014), including topical chemotherapy such as imiquimod (Williams 2017
), 5-fluorouracil (5-FU) (Arits 2013), ingenol mebutate (Nart 2015) and photodynamic therapy (PDT) (Roozeboom 2016
). Non-surgical treatments are most frequently used for superficial forms of BCC, with one head to head trial
suggesting topical imiquimod is superior to PDT and 5-FU (Jansen 2018). Although non-surgical techniques are
increasingly used, they do not allow histological confirmation of tumour clearance, and their efficacy is dependent on
accurate characterisation of the histological subtype and depth of tumour and so a baseline diagnostic biopsy can be
helpful. The 2007 systematic review of BCC interventions found limited evidence from very small RCTs for these
approaches (Bath-Hextall 2007b), which have only partially been filled by subsequent studies (Bath-Hextall 2014; Kim 2014; 
Roozeboom 2012). Most BCC trials have compared interventions within the same treatment class, and few have
compared medical versus surgical treatments (Kim 2014).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with predetermined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Observational
studies suggest low recurrence rates for small, low risk lesions treated with cryotherapy or curettage and
electrodesiccation (recurrence rates < 2%). Estimates of recurrence after Mohs microsurgery, surgical excision, or
radiotherapy, which are likely to have been evaluated in higher risk populations, have shown pooled recurrence
rates of 3%, 5.4% and 6.4%, respectively with overlapping confidence intervals; the review authors advise caution
when comparing results across treatments (Lansbury 2013).
Index test(s)
Optical coherence tomography (OCT) is a non–invasive technology that was first applied to the diagnosis of skin
lesions in 1997 (Welzel 1997). The technique uses a handheld probe based on the same principle as ultrasound, but
instead of using sound waves, it uses low–coherence interferometry to measure the optical scattering of
near–infrared (1310 nm) light waves from under the surface of the skin; an image similar to a sonograph is created
based on multiple parallel scans (Hussain 2015; Olsen 2015) (Figure 3 and Figure 4). Both 2D and 3D images can be
created. There are a number of different types of OCT, the most commonly used in dermatological research is frequency
domain or swept source OCT where several scans are taken using a rotating optical mirror to construct multi-slice scans;
these can create vertical cross–sectional slices of skin, or ‘en–face’ images of horizontal layers (as with Reflectance Confocal
Microscopy, RCM).
A challenge for any imaging device is the trade-off between high resolution (clearer image) and depth of penetration of
the layers of the skin (Olsen 2015). Conventional OCT devices can achieve penetration depths of up to 2 mm, with
respective axial and lateral resolutions of up to 7.5µm and 5µm (Hussain 2015; Olsen 2015). Skin features that can
be visualised include the epidermis, the dermal-epidermal junction (DEJ), the upper or papillary dermis, the lower or
reticular dermis, blood vessels travelling through the upper dermis, skin appendages, such as hair follicles and
sebaceous glands, and the nail unit and nail plate (DermNet New Zealand 2013). High-definition OCT can achieve
axial and lateral resolutions of 3µm (thereby allowing single cells to be visualised) at a depth of up to 0.57mm (Boone 2015; 
Hussain 2015; Olsen 2015).
OCT is not routinely used in current practice (NICE 2015a). It is considered to be of particular potential for the
differentiation of non-pigmented lesions as pigmented lesions demonstrate regular scattering patterns that inhibit
the differentiation of malignant from benign lesions (Gambichler 2015b; Olsen 2015). Preliminary work using HD
OCT in melanocytic lesions suggests that pagetoid cells, fusion of rete ridges, and junctional or dermal nests with
atypical cells, or both, are more prevalent in melanomas compared to benign nevi (Gambichler 2015a). A recent
review suggests that eight characteristics associated with BCC have been variously reported for conventional OCT
including: disruption of layering, hypo-reflective rounded areas surrounded by a hyper-reflective halo ('honeycomb'
structures), palisading at margin, dilated vessels, well-circumscribed black/signal poor areas, intact DEJ with
underlying dark rounded areas, thinning of the epidermis, horizontal signal intense cords (Figure 5) (Hussain 2015).
While there are no data to suggest that conventional OCT can discriminate between BCC subtypes (Calin 2013; Hussain
2015), HD OCT has been advocated as a tool to do so, however results to date have been conflicting (Boone 2012; 
Gambichler 2014; Hussain 2015). Features thought to describe cSCC lesions by conventional OCT include
destruction of the epidermis and thickened epidermal layer, however these are also visualised in actinic keratosis
and so are not thought to be adequately discriminating (Reggiani 2015). Features thought to be useful for identifying
cSCC by HD OCT include disruption of the DEJ, disarranged epidermal pattern in the absence of honeycomb
structures (Boone 2015), and very bright irregularly broadened cell outlines masking the nucleus, which are thought
to represent atypical keratinocytes (Reggiani 2015).
Internationally, there are a large number of companies producing different commercially available OCT devices, across a
range of medical specialities; Gambichler 2015b lists nine different devices applied in dermatology. Imaging can reportedly
be undertaken by clinicians or technicians, taking around 30 seconds to scan a lesion, with results immediately available for
review and discussion with patients. No information on the cost of OCT was identified.
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Clinical Pathway 
The diagnosis of skin lesions occurs in primary, secondary, and tertiary care settings by both generalist and specialist
healthcare providers. In the UK, people with concerns about a new or changing lesion will either present to their
general practitioner or directly to a specialist in secondary care, which could include a dermatologist, plastic surgeon,
general surgeon or other specialist surgeon (such as an ear, nose, and throat (ENT) specialist or maxillofacial
surgeon), or ophthalmologist (Figure 6). Current UK guidelines recommend that all suspicious pigmented lesions
presenting in primary care should be assessed by taking a clinical history and visual inspection using the revised
seven-point checklist (MacKie 1990); lesions suspected to be melanoma (Chao 2013; Marsden 2010; NICE 2015b) or
cSCC (London Cancer Alliance 2013) should be referred for appropriate specialist assessment within two weeks.
Generalist care providers increasingly carry out management of low-risk BCC (CCAAC Network 2008).
The specialist clinician will use history-taking, visual inspection of the lesion (in comparison with other lesions on the skin),
and usually dermoscopy to inform a clinical decision. If melanoma or cSCC is suspected, then urgent excision is
recommended. Lesions such as BCC may be referred for a diagnostic biopsy, followed by appropriate treatment or further
surveillance or reassurance and discharge.
Prior test(s)
Fundamental to the diagnosis of skin cancer is history-taking and clinical examination. In the UK, this is typically
done at two decision points – first in the GP surgery where a decision is made to refer or not to refer, and then a
second time by a dermatologist or other professional in secondary care where a decision is made to biopsy or
not. However, a range of technologies have emerged to aid diagnosis to reduce the number of biopsies.
Dermoscopy in particular has become the most widely used tool for clinicians to try to obtain an accurate
assessment of melanoma following visual inspection (Argenziano 1998; Argenziano 2012; Haenssle 2010; Kittler 2002
), although is less well established for BCC or cSCC diagnosis (Dinnes 2018a).
Visual inspection of the skin is undertaken iteratively, using both implicit pattern recognition (non-analytical
reasoning) and more explicit ‘rules’ based on conscious analytical reasoning (Norman 2009), the balance of which
will vary according to experience and familiarity with the diagnostic question. Various attempts have been made to
formalise the “mental rules” involved in analytical pattern recognition for melanoma, ranging from a setting out of
lesion characteristics that should be considered (Friedman 1985; Sober 1979) to formal scoring systems with explicit
numerical thresholds. The revised seven-point checklist, for example, assesses change in lesion size, shape, colour,
inflammation, crusting or bleeding, sensory change, or diameter ≥ 7 mm (MacKie 1990). Other available tools
include the ABCD(E) approach (presence of features: asymmetry, border, colour, diameter, evolution) (Friedman 1985; 
Thomas 1998) and 'ugly duckling' sign (Grob 1998). For keratinocyte skin cancers, visual inspection relies primarily
on pattern recognition and accuracy has been shown to vary according to the expertise of the clinician. Primary care
physicians have been found to miss over half of BCC (Offidani 2002) and to inappropriately diagnose one third of
BCC (Gerbert 2000). In contrast, an Australian study found that trained dermatologists were able to detect 98% of
BCC, but with a specificity of only 45% (Green 1988).
Dermoscopy is a non-invasive, in vivo technique that uses a hand-held microscope and incident light (with or without oil
immersion) to reveal subsurface images of the skin at increased magnification of x 10 to x 100 (Kittler 2011). Although
widely used, the accuracy of dermoscopy largely depends on the experience and training of the examiner (Binder 1997; 
Kittler 2002; Kittler 2011). Pattern analysis (Pehamberger 1987; Steiner 1987) is thought to be the most specific and
reliable technique to aid dermoscopy interpretation when used by specialists (Maley 2014); however, dermoscopic
histological correlations have been established and diagnostic algorithms have been developed to improve
melanoma diagnosis, using features based on colour, aspect, pigmentation pattern, and skin vessels, including the
ABCD rule for dermoscopy (Nachbar 1994; Stolz 1994), the Menzies approach (Menzies 1996), the seven-point
dermoscopy checklist (Annessi 2007; Argenziano 1998; Argenziano 2001; Gereli 2010), and the three-point checklist (
Gereli 2010). Similar algorithms have been developed to aid in the detection of BCC (Menzies 2000; Navarrete-Dechent
2016).
The accuracy, and comparative accuracy, of visual inspection and dermoscopy and their associated scoring systems
for the detection of both melanoma and keratinocyte skin cancers is summarised in three reviews in this series (Dinnes
2018a; Dinnes 2018b; Dinnes 2018c).
Role of index test(s)
Used in conjunction with clinical or dermoscopic suspicion of malignancy, or both, OCT may provide a means of
reducing the number of false positive diagnoses and therefore reduce unnecessary biopsies in suspected BCC (Gambichler
2015b; Hussain 2015; Reggiani 2015). OCT is said to lie within the ‘imaging gap’ between high resolution ultrasound
and RCM in terms of depth of penetration of the skin and resolution of the resulting image (Olsen 2015; Themstrup 2015
). OCT has a lower depth of penetration but higher resolution in comparison to ultrasound. Compared to RCM, OCT
uses a longer wavelength (830nm as opposed to 1305nm for OCT), has considerably deeper penetration (RCM < 300
µm; OCT < 2 mm) meaning it can visualise deeper into the dermis, has a greater depth of focus (RCM 3-5 µm; OCT 1
mm), and wider basic field of view (RCM basic 500 x 500 µm in the horizontal plane; OCT basic 6 x 6 mm). However
OCT has lower lateral resolution in comparison to RCM (RCM 1 µm, cellular; OCT 7.5 µm, near cellular), although
newer high definition OCT reportedly has the capacity to visualise most RCM features (Olsen 2015). Both OCT and RCM
have fields of view that are extendible by mechanical scanning and image mosaicking, although for equivalent fields of view
3D imaging is much faster with OCT (RCM for mosaicked field of view and stack > 10 min; OCT 6 cross-sectional frames per
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second, < 2 min for 6 x 6 x 2mm volume). OCT may therefore be well placed to provide a combination of diagnostic
information that cannot be retrieved with either confocal microscopy or ultrasound alone. Furthermore, the speed of OCT
imaging allows rapid assessment of multiple lesions potentially obviating the need for multiple biopsies. In addition to
diagnosis, OCT has the potential to inform therapeutic decisions for patients with a diagnosis of BCC, by determining the
thickness of lesions, and when using HD OCT potentially also establishing the subtype of BCC. Once diagnosed, superficial
BCC can be treated using nonsurgical treatments (listed in Target condition being diagnosed), which could be
advantageous for multiple lesions or those arising on cosmetically critical sites e.g. face (Powell 2000). Excisional
surgery and Mohs micrographic surgery are the most successful treatments for nodular / infiltrative BCC, although
smaller nodular BCCs in low risk areas can also be treated with topical treatments (Williams 2017). Therefore the ability to
confirm the subtype of BCC in these patients using a fast and non–invasive approach is attractive since it could reduce
treatment-related morbidity, and possibly reduce the cost of management.
The potential role of OCT to diagnose melanomas is less clear, given that its resolution is insufficient to visualise
melanocytes, a key feature for the diagnosis of melanoma. However, OCT has been suggested to allow the
identification of architectural characteristics that are useful for differentiating malignant from benign melanocytic
lesions (Gambichler 2007). Although the primary aim in diagnosing potentially life-threatening conditions such as melanoma
is to minimise false negative diagnoses (to avoid delay to diagnosis and even death), a test that can reduce false positive
clinical diagnoses without missing true cases of disease has patient and resource benefits. False-positive clinical diagnoses
not only cause unnecessary morbidity from the biopsy, but also increase patient anxiety. Pigmented lesions are common so
the resource implication for even a slight increase in the threshold to excise lesions in populations where melanoma rates are
increasing, will avoid a considerable healthcare burden to both patient and healthcare provider, as long as such lesions turn
out to be harmless.
A delay in the diagnosis of BCC as a result of a false-negative test is usually not as serious as for melanoma because BCC
is usually slow-growing and very unlikely to metastasise. However, delayed diagnosis can result in a larger and more
complex excision. Very sensitive tests for BCC, which compromise on lower specificity leading to a high false-positive rate,
are likely to result in an enormous burden of skin surgery because BCC is so common, which the National Health Service
(NHS) will struggle to cope with, so a balance between sensitivity and specificity is needed. With the greater potential for
cSCC to metastasise, delayed diagnosis can be a much more serious problem, ultimately impacting on long-term prognosis.
A test that can accurately distinguish between BCC, cSCC and melanoma could reduce the time to diagnosis, better inform
appropriate treatment decisions in those who need it, and could avoid unnecessary surgical procedures.
OCT has also been investigated for its ability to identify lesion thickness, define tumour margins, and to assist in Mohs
surgery, reducing the number of layers needed to remove the lesion (De Carvalho 2018; Gambichler 2015b; Hussain 2015; 
Olsen 2015); however, these applications are not considered in this review.
Alternative test(s)
Several other non-invasive diagnostic technologies that are not routinely used in practice may also have a role for the
diagnosis of skin cancer in a specialist setting, and these are being reviewed as part of our series of Cochrane DTA
reviews on the diagnosis of melanoma and keratinocyte cancers: visual inspection and dermoscopy (Dinnes 2018a; Dinnes
2018b; Dinnes 2018c), reflectance confocal microscopy (RCM) (Dinnes 2018d; Dinnes 2018e), high-frequency
ultrasound (HFUS) (Dinnes 2018f), and computer-aided diagnosis (CAD) techniques that make use of dermoscopic
or spectroscopic images, or other spectroscopic data (Ferrante di Ruffano 2018a).
RCM in particular is emerging as a potential alternative or adjunct to dermoscopy for the diagnosis of skin cancer (Edwards
2016), and can be used to visualise horizontally sectioned images of the skin at a cellular lateral resolution of ~1
micron, in vivo to the depth of the upper dermis. The contrast for the monochrome images produced is achieved by
the variation of the optical properties within the skin when illuminated by a near-infrared light (830 nm); the greatest
contrast is achieved from melanin, so that RCM is advocated as being particularly useful for assessing pigmented
lesions (Dinnes 2018e).
Computer-assisted diagnosis (CAD) or artificial intelligence-based techniques analyse either dermoscopic or
spectroscopic images, or other forms of spectroscopic data (such as diffuse reflectance or electrical impedance
measurements), using predefined algorithms to process and manipulate acquired images to identify the features that
discriminate malignant from benign lesions (Esteva 2017; Rajpara 2009). A variety of spectroscopy-based tests
have been developed and evaluated in both primary and secondary care settings, including SIAscopy™ (Moncrieff 2002; 
Walter 2012), MelaFind® (Hauschild 2014; Monheit 2011; Wells 2012), and Nevisense™ (Malvehy 2014). Ultrasound
relies on the measurement of sound wave reflections from the tissues of the body. At lower frequencies, the deeper
structures of the body such as the internal organs can be visualised, while high frequency ultrasound (HFUS) with
transducer frequencies of at least 20MHz has a much lower depth of tissue penetration but produces a higher
resolution image of tissues and structures closer to the skin surface. HFUS may therefore offer additional diagnostic
information compared to other technologies, however evidence to date is scarce and of generally poor quality (Dinnes
2018f).
Evidence permitting, the accuracy of available tests will be compared in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison of commonly used diagnostic strategies where tests may be
used singly or in combination.
Alternative tests identified as potential candidates for review but for which no eligible studies were found include
volatile organic compounds (including canine odour detection) (Abaffy 2010; Church 2001; D'Amico 2008; Gallagher 2008; 
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Kwak 2013; Williams 1989), and gene expression analysis (Ferris 2012; Wachsman 2011).
We also considered and excluded a number of tests from this review including tests used in the context of monitoring people,
such as total body photography of those with large numbers of typical or atypical naevi, and histopathological confirmation
following lesion excision. The latter is the established reference standard for melanoma diagnosis and will be one of the
standards against which the index tests are evaluated in these reviews.
Rationale
Our series of reviews of diagnostic tests used to assist the clinical diagnosis of melanoma and of the keratinocyte skin
cancers BCC and cSCC, aims to identify the most accurate approaches to diagnosis and provide clinical and policy
decision-makers with the highest possible standard of evidence on which to base decisions. With increasing rates of
melanoma incidence and the push towards the use of dermoscopy and other high resolution image analysis in primary
care, the anxiety around missing early cases needs to be balanced in order to avoid referring too many people with
benign lesions for a specialist opinion. For keratinocyte skin cancers, the increasing availability of a wider range of tests
means these technologies must be evaluated for their ability to differentiate and appropriately triage keratinocyte skin
cancers, to avoid sending too many people with benign or low risk lesions for a specialist opinion and possible excision
or biopsy, whilst not missing those people who have lesions that require treatment. It is questionable whether all skin
cancers picked up by sophisticated techniques, even in specialist settings, help to reduce morbidity and mortality or
whether newer technologies run the risk of increasing false-positive diagnoses. It is also possible that use of some
technologies, e.g. widespread use of dermoscopy in primary care with no training, could actually result in harm by
missing skin cancers if they are used as replacement technologies for traditional history-taking and clinical examination
of the entire skin. Many branches of medicine have noted the danger of such 'gizmo idolatry' amongst doctors (Leff 2008).
Despite having been first applied to skin lesions in the 1990s, OCT - and particularly HD-OCT - is a fast developing
novel technology, that if accurate enough could have considerable potential to assist in the non-invasive diagnosis of
skin cancers. Existing systematic reviews of OCT focus on the important question of synthesising the histological and
imaging correlates of skin cancer diagnoses; however this emphasis means their selection and presentation of test
accuracy evidence is not as rigorous and comprehensive as would be expected in systematic reviews of diagnostic test
accuracy. In addition, none reported undertaking any assessment of quality assessment or attempted meta-analysis (Calin
2013; Gambichler 2015b; Hussain 2015; Olsen 2015), and all are limited by out of date searches (the most recent finishing in
May 2015, Olsen 2015). In this rapidly advancing field, there is a need for an up-to-date analysis of the accuracy of OCT for
the diagnosis of melanoma and keratinocyte skin cancer.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
melanoma (Dinnes 2015a) and for the diagnosis of keratinocyte skin cancers (Dinnes 2015b). The Background and
Methods sections of this review therefore use some text that was originally published in the protocol (Dinnes 2015a; Dinnes
2015b) and text that overlaps some of our other reviews (Dinnes 2018d; Dinnes 2018e; Dinnes 2018f; Ferrante di Ruffano
2018a; Ferrante di Ruffano 2018b).
Objectives 
To determine the diagnostic accuracy of OCT for the detection of cutaneous invasive melanoma and intraepidermal
melanocytic variants, basal cell carcinoma (BCC), or cutaneous squamous cell carcinoma (cSCC) in adults.
Secondary objectives
To determine the diagnostic accuracy of OCT in comparison to standard diagnostic practice for the detection of either
cutaneous invasive melanoma and intraepidermal melanocytic variants, basal cell carcinoma, or cutaneous squamous cell
carcinoma in adults.
To determine the diagnostic accuracy of OCT for the detection of invasive melanoma alone.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as
outlined in our generic protocol (Dinnes 2015a; Dinnes 2015b); however, our ability to investigate these and other sources of
heterogeneity is necessarily limited by the data available for each reviewed test.
i. Population characteristics
general versus higher risk populations
patient population: primary/secondary/specialist unit
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
in person versus remote image-based test interpretations
the nature of and definition of criteria for test positivity
observer experience with the index test
iii. Reference standard characteristics
reference standard used
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whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005), however we
did not include studies that compared results for malignant lesions to those for healthy skin (i.e. with no lesion present);
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included fewer than five disease
positive or five disease negative cases. The size threshold of five is arbitrary. However such small studies are unlikely to add
precision to estimate of accuracy.
Participants
We included studies in adults with pigmented skin lesions or lesions suspicious for melanoma, for BCC, or for cSCC.
We excluded studies that recruited only participants with malignant diagnoses. We excluded studies with more than 50% of
participants aged 16 and under.
Index tests
Studies evaluating optical coherence tomography alone, or optical coherence tomography in comparison to visual inspection
or dermoscopy, or both, were included.
All established algorithms or checklists to assist diagnosis were included. Studies developing new algorithms or
methods of diagnosis (i.e. derivation studies) were included if they used a separate independent 'test set' of participants
or images to evaluate the new approach. Studies that did not report data for a separate test set of patients or images
were included only if the lesion characteristics investigated had previously been suggested as associated with
melanoma, BCC, or with cSCC and the study reported accuracy based on the presence or absence of particular
combinations of characteristics. Studies using a statistical model to produce a data driven equation, or algorithm based
on multiple diagnostic features, with no separate test set were excluded. Studies using cross-validation approaches
such as 'leave-one-out' cross-validation (Efron 1983) were excluded. Studies evaluating the accuracy of subjective
assessment of the presence or absence of individual OCT characteristics or morphological features, with no overall
diagnosis of malignancy, were also excluded.
No exclusions were made according to test observer.
Target conditions
The target conditions were defined as the detection of:
any form of invasive cutaneous melanoma or atypical melanocytic intraepidermal variants (i.e. including melanoma in situ,
or lentigo maligna, which has a risk of progression to invasive melanoma)
basal cell carcinoma (all types)
cutaneous squamous cell carcinoma (invasive)
any skin cancer or other lesion requiring excision (including melanoma or atypical intraepidermal melanocytic variants,
severely dysplastic melanocytic lesions, keratinocyte skin cancer, and any other skin cancer).
Reference standards
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The ideal reference standard was histopathological diagnosis of the excised lesion or biopsy sample in all eligible lesions. A
qualified pathologist or dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing
a minimum dataset to include the histopathological features of melanoma to determine the American Joint Committee on
Cancer (AJCC) Staging System (e.g. Slater 2014). We did not apply the reporting standard as a necessary inclusion
criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
lesion excision or biopsy is unlikely to be carried out for all benign-appearing lesions within a representative population
sample. Therefore, we accepted clinical follow-up of benign-appearing lesions as an eligible reference standard, whilst
recognising the risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ) in our
quality assessment of studies.
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated (Appendix 2). The search strategy was designed to
capture studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was applied to
the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to assess treatment
effectiveness. A sample of 300 records that would be missed by applying this filter was screened and the filter adjusted to
include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for the staging tests reduced the overall
numbers by around 6000. The final search strategy, incorporating the filter, was subsequently applied to all bibliographic
databases as listed below. The final search result was cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this study is not indexed on MEDLINE. The Information
Specialist devised the search strategy, with input from the Information Specialist from Cochrane Skin. No additional limits
were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied. Update searches will be time and resource dependent.
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Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JD or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
3) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JD or NC) to all full text articles, disagreements were resolved by consensus or by a third party (JJD,
CD, HW, and RM). Authors of eligible studies were contacted when insufficient data were presented to allow for the
construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JD, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by
a third party (JJD, CD, HW, and RM).
Authors of included studies were contacted where information related to the target condition (in particular to allow the
differentiation of invasive cSCC from ‘in situ’ variants) or diagnostic threshold were missing. Authors of conference abstracts
published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper was identified, we
marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 4 for full details of items, responses and summary judgement criteria). The modified QUADAS-2
tool was piloted on a small number of included full text articles. One clinical (as detailed above) and one methodologist
reviewer (JD, NC or LFR) independently assessed quality for the remaining studies; any disagreement was resolved by
consensus or by a third party where necessary (JJD, CD, HW, and RM).
Statistical analysis and data synthesis
Due to paucity of data and differences in thresholds used to define test positivity, no meta-analysis was undertaken for the
diagnosis of melanoma or for the diagnosis of cSCC. Statistical pooling was undertaken for the diagnosis of BCC.
For the diagnosis of cSCC at each threshold, any other skin cancers (i.e. BCC) that were included in the study and that were
incorrectly identified as cSCCs (i.e. positive on OCT) were considered as true negative test results rather than as false
positives, on the basis that excision of such lesions may still have been appropriate for the participants concerned. For the
diagnosis of BCC however, any other skin cancers (for example melanomas or cSCCs) in the ‘disease negative’ group that
were incorrectly identified by OCT as BCCs were kept as false positive results. This decision was taken on the basis that the
clinical management of a lesion considered to be a BCC (for example, initiation of Mohs micrographic surgery, destructive
techniques or non-surgical treatments) could be quite different to that for a melanoma or cSCC and could potentially lead to a
negative outcome for those concerned.
Estimates of sensitivity and specificity were plotted on coupled forest plots for each threshold under consideration. Our unit of
analysis was the lesion rather than the person. This is because (i) in skin cancer initial treatment is directed to the lesion
rather than systemically (thus it is important to be able to correctly identify cancerous lesions for each person), and (ii) it is
the most common way in which the primary studies reported data. Although there is a theoretical possibility of correlations of
test errors when the same people contribute data for multiple lesions, most studies include very few people with multiple
lesions and any potential impact on findings is likely to be very small, particularly in comparison with other concerns
regarding risk of bias and applicability. For each analysis, only one dataset was included per study to avoid multiple counting
of lesions.
To allow statistical pooling where multiple thresholds per algorithm were reported (Wahrlich 2015), we analysed data
separately using each threshold. For tests where commonly used thresholds were reported we estimated summary
operating points (summary sensitivities and specificities) with 95% confidence and prediction regions using the bivariate
hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were available for the model to converge
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the model was simplified by assuming no correlation between estimates of sensitivity and specificity (Takwoingi 2017).
Data on the accuracy of visual inspection and/or dermoscopy was included to allow comparisons of tests, but only if
reported in the included studies of OCT due to the known substantial unexplained heterogeneity in all studies of the
accuracy of dermoscopy (Dinnes 2018b). The bivariate model was extended by addition of covariates to allow for differences
in sensitivity and specificity between OCT and visual inspection and/or dermoscopy, with the significance of differences being
assessed using a single likelihood ratio test comparing models with and without the covariates.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity. Insufficient
numbers of studies were identified to allow meta-regression to investigate potential sources of heterogeneity.
Sensitivity analyses
No sensitivity analyses were done.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), no tests to detect publication bias were performed.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer.
Figure 7 documents a PRISMA flow diagram of search and eligibility results. Of the 1051 studies assessed, exclusions were
due to lack of test accuracy data (184 studies), or because they were derivation studies (141 studies), evaluated an ineligible
index test (126 studies), included ineligible populations (83 studies), assessed an ineligible target condition (78 studies), had
fewer than 5 malignant cases (72 studies) or did not meet our requirements for eligible reference standards (i.e. at least 50%
of all participants with benign lesions had to have either a histological diagnosis or clinical follow up to determine the final
diagnosis (76 studies)). A total of 43 studies were tagged as potentially eligible for this review; ultimately 5 publications
(reporting 5 studies) were included. A list of the 38 studies excluded from this review with reasons for exclusion is provided in
Characteristics of excluded studies, with a list of all studies excluded from the full series of reviews available as a separate
pdf.
Across all skin cancer DTA reviews, the corresponding authors of 86 studies were contacted and asked to supply further
information to allow study inclusion (n = 37) to clarify diagnostic thresholds (n = 18) or target condition definition (n = 30).
Characteristics of included studies
This review reports on a total of 5 cohorts of participants with lesions suspected of skin cancer, published in 5 study
publications, and providing 9 datasets for OCT, two for visual inspection and two for dermoscopy. A description of thresholds
used for diagnosis across the studies is provided in Table 2 and summary study details are presented in Appendix 5.
The five included studies consisted of four prospective case series and one study in which the design was unclear (
Wahrlich 2015). Three were conducted in Germany (Gambichler 2015; Ulrich 2015; Wahrlich 2015), one in the
Netherlands (Wessels 2015), and one in the US (Markowitz 2015). Three studies were funded by OCT
manufacturers (Gambichler 2015; Markowitz 2015; Ulrich 2015), in Wahrlich 2015 the OCT device was provided by the
manufacturer, and no company funding was reported in Wessels 2015. Two studies were conducted in participants
with pigmented (Wessels 2015) or melanocytic lesions (Gambichler 2015) and focused on identification of
melanomas. The remaining three studies (Markowitz 2015; Ulrich 2015; Wahrlich 2015) studied series of non-
pigmented lesions (Markowitz 2015 focused on head and neck lesions), two focusing on 'pink' lesions suspected of
being BCCs (Markowitz 2015; Ulrich 2015) and the third selecting nonpigmented lesions according to their
histological diagnosis (Wahrlich 2015). All five studies analysed lesions selected for excision or biopsy, two of
which focused on clinically challenging lesions (Markowitz 2015; Ulrich 2015). The studies also varied in the
degree of testing performed prior to study inclusion and performance of the OCT scan: the two melanoma studies
included participants with clinical suspicion of melanoma and either prior dermoscopy in all (Gambichler 2015) or
some (Wessels 2015) study participants. All three studies of non-pigmented lesions reported visual inspection as a
prior test, with the case-control study also reporting dermoscopy and histology (Wahrlich 2015), while the two
prospective studies performed dermoscopy and histology during the study (Markowitz 2015; Ulrich 2015).
A total of 402 participants with 529 lesions were included, the numbers included in each study ranging from 33 to
164 participants and 40 to 256 lesions. The prevalence of disease was 23% (Wessels 2015) and 27% (Gambichler 2015
) in the two melanoma studies (both of which included only benign nevi in the disease negative group), and disease
prevalence ranged from 58% (Wahrlich 2015) to 61% (Markowitz 2015) in the studies of BCC. Of the three BCC
studies, one did not describe diagnoses in the disease negative group (Markowitz 2015); one included participants
with cSCC, Bowen’s disease, and actinic keratosis only (Wahrlich 2015); while Ulrich 2015 included participants with
Bowen's disease, actinic keratosis, and inflammatory diseases such as psoriasis and eczema amongst others (no cSCC
lesions were included). One of these, Wahrlich 2015, provided the only dataset available for the detection of cSCC, with a
prevalence of 18%.
Four studies evaluated conventional swept source OCT (all with similar resolutions and tissue penetration
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capacities), and one evaluated high-definition (HD) OCT for diagnosis of melanoma (Gambichler 2015). A number of
different thresholds for test positivity were assessed across the studies (Table 2). For the detection of melanoma, Gambichler
2015 developed a new scoring system based on the presence or absence of risk features and protective features as derived
from existing literature; the method of selection of the numeric cut-off for test positivity was not described, and Wessels 2015
derived the optimal attenuation coefficient for detection of melanoma using Youden’s index. For the diagnosis of
BCC, two studies described a number of OCT characteristics considered indicative of BCC, which were used by
observers to form an overall clinical impression of BCC or not BCC (Markowitz 2015; Ulrich 2015). Both studies also reported
accuracy for in person visual examination alone and for visual examination plus dermoscopic diagnosis. Wahrlich 2015
assessed similar OCT characteristics (Table 2), assigning a score to each based on the clarity of visualisation of
each feature (named the ‘Berlin Score’). Scores based on a separate training set of lesions were used to identify
limit values (T1,T2) to differentiate BCCs from cSCCs, actinic keratosis and Bowen's disease (Wahrlich 2015).
Four studies reported image-based diagnosis with OCT (i.e. diagnosis based on OCT scans interpreted remotely from the
patient concerned); with only Ulrich 2015 describing OCT scans interpreted in real-time following clinical
examination and then dermoscopy of the lesions. One study (Wahrlich 2015) described observer qualifications
(with interpretation by a dermatopathologist), and three described observers as experienced or regular users of
an OCT device (Gambichler 2015; Ulrich 2015; Wahrlich 2015). Only Wahrlich 2015 described any test failures (see
Methodological quality of included studies). In all studies the reference standard diagnosis was made by histology alone.
Methodological quality of included studies
Overall study quality was moderate or unclear, with considerable concerns regarding the clinical applicability of results
(Figure 8 and Figure 9).
Three of the five studies were at low risk of bias for participant selection; the remaining two did not clearly describe
consecutive patient recruitment and one may have used a case-control type design. All studies were judged as having
high concern for applicability of the patient selection; all scored high concern on both QUADAS items apart from one
recruiting a representative range of non-pigmented lesions (Ulrich 2015), and one (Wahrlich 2015) which avoided recruitment
of participants with multiple lesions. All studies included only lesions selected for excision, however.
Two studies were at low risk of bias in the index test domain (Markowitz 2015; Ulrich 2015). Of the remaining three,
one did not enforce blinded interpretation of the index test (OCT interpretation by the dermatopathologist following
histology (Wahrlich 2015)), one used a data driven threshold (Wessels 2015) and one did not describe the
approach to selection of the numeric threshold used (Gambichler 2015).
Four studies were at high concerns around the applicability of the index test. All studies reported the thresholds
used to define test positivity; however, in four studies the application of the test was judged as not clinically
applicable due to the use of image-based diagnosis remote from the study participants. The expertise of the
clinician interpreting the OCT scan was not reported in two studies (Markowitz 2015; Wessels 2015),
Furthermore, one reported blinding to all other clinical information (Gambichler 2015), and two did not clearly
describe what information was provided to test observers (Wessels 2015; Markowitz 2015).
All studies reported the use of an acceptable reference standard, but not one clearly reported blinding of the reference
standard either to the OCT result or to the referral diagnosis, based on clinical examination or dermoscopy (although the
latter did not contribute to overall judgements of applicability). For the applicability of the reference standard, no study
reported using expert diagnosis to provide the final diagnosis of any lesion but only one reported histopathology
interpretation by an experienced dermatopathologist; the remainder scored as unclear concerns regarding applicability of the
reference standard.
Three studies were judged at low risk of bias in the flow and timing domain apart; Ulrich 2015 reported the exclusion of
lesions with missing histology and Wahrlich 2015 described exclusion of three participants due to awkward lesion site,
different scan 'heights' and shadow artefacts in the discussion section of the paper. None of the other studies described any
failure to successfully image a lesion, raising the possibility that such cases occurred but were not reported.
For the two studies comparing OCT with visual inspection and dermoscopy, both reported consecutive diagnoses using each
of the three and blinding between tests was not enforced in either (this did not contribute to the overall assessment of risk of
bias). The clinical applicability of the application of the tests was of low concern in Ulrich 2015. The same item was scored as
unclear Markowitz 2015 where visual inspection and dermoscopy diagnoses were both undertaken in person and OCT
interpretation was done remotely with no indication as to whether the diagnosis was undertaken by the same test observer
nor whether clinical or dermoscopic images were provided to assist OCT diagnosis.
Findings
All results below refer to the detection of skin cancer in lesions, not in participants (see Statistical analysis and data
synthesis).
Detection of invasive melanoma or melanoma in situ
Two studies analysed 133 lesions for the detection of 36 melanomas (Figure 10). The single study evaluating
conventional swept source OCT for the detection of melanoma or intraepidermal melanocytic variants in 40 lesions
selected for excision reported sensitivity of 89% (95% CI: 52, 100%) and specificity of 61% (95% CI: 42, 78%) at an
attenuation coefficient of 5.4mmˉ¹ (Wessels 2015). In their discussion, the authors reported an inability to visualise some
architectural features (such as brown globules, rete ridges or vertical icicle-shaped structures) useful to making a melanoma
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diagnosis, due to the insufficient resolution provided by the conventional OCT system.
Using HD OCT and their own scoring system for the presence of recognised OCT characteristics in a sample of 93 lesions,
Gambichler 2015 reported sensitivity of 74% (95% CI: 54, 89%) and specificity of 92% (95% CI: 83, 97%) for the detection of
melanoma or atypical intraepidermal melanocytic variants at a score of ≥ -1 and < -1.5, with sensitivity increasing to 80%
(95% CI: 59, 93%) and specificity to 93% (95% CI: 84, 98%) for the detection of invasive melanoma alone; both melanoma in
situ lesions included in the study were misclassified as negative on OCT.
Detection of BCC
All three studies used conventional swept source OCT for the detection of 237 BCCs in 396 analysed lesions. Wahrlich
2015’s quantitative scoring of OCT characteristics resulted in a sensitivity of 97% (95% CI: 82, 100%) and specificity
76% (95% CI: 53, 92%) at a Berlin score of ≥ 8, with lower sensitivity (66% (95% CI: 46, 82%)) and higher specificity
(86% (95% CI: 64, 97%)) at the higher score of ≥ 12 (Figure 10). Four of the five false positive results at ≥ 8 and all three at ≥
12 were cSCC lesions.
Markowitz 2015 and Ulrich 2015 both reported observer diagnosis of BCC based on the subjective judgement of the
presence of specified OCT features (Table 2), in clinically challenging non-pigmented 'pink' lesions, and compared this
to diagnosis by visual inspection alone and by visual inspection plus dermoscopy (Figure 11). Meta-analysis of the 346
lesions (including 273 BCCs) produced a pooled sensitivity for OCT of 95% (95% CI: 91, 97%) and pooled specificity of 77%
(95% CI: 69, 83%). Neither study reported including any cSCC lesions (benign diagnoses not described in Markowitz 2015)
owing to the fact that both studies limited participant inclusion to erythematous / pink lesions which are uncommon
presentations for invasive cSCC.
OCT was significantly more accurate for the diagnosis of BCC in comparison to visual inspection alone (P = 0.007; Figure 11
and Figure 12); visual inspection showing a pooled sensitivity of 80% (95% CI: 55, 93%) and specificity 37% (95% CI: 24,
52%). OCT was also significantly more accurate for the diagnosis of BCC in comparison to visual inspection with the addition
of dermoscopy (P < 0.001; Figure 11, Figure 13); visual inspection and dermoscopy having a pooled sensitivity of 86% (95%
CI: 76, 92%) and specificity of 55% (95% CI: 46, 63%).
Detection of cSCC
One study reported OCT results for the diagnosis of 9 cSCCs amongst a group of 50 lesions consisting of BCCs
(29), actinic keratoses (5) and Bowen's disease (7) (Wahrlich 2015). Using the quantitative scoring of conventional
swept source OCT characteristics reported above, sensitivity was 56% (95% CI: 21, 86%) and specificity was 100%
(91, 100%) at a score of ≥ 8, with a lower sensitivity using a score of ≥ 12 (33%, 95% CI: 7, 70%) (Figure 10). BCC lesions
with positive OCT results were considered as true negatives (not as false positives) as explained in the Statistical analysis
and data synthesis section above.
Investigations of heterogeneity
We were unable to undertake formal investigations of heterogeneity due to insufficient study numbers.
Discussion 
Summary of main results
This review aimed to assess the accuracy of optical coherence tomography as an aid to diagnosing melanoma,
BCC, or cSCC in adults. We included five studies evaluating optical coherence tomography, two of which also
evaluated visual inspection and visual inspection combined with dermoscopy (Summary of findings table 1).
Studies were generally of moderate to unclear methodological quality, and poor in terms of the applicability of their results to
a clinical setting. For risk of bias, there was a lack of clarity of description of a number of different items across the studies
including: recruitment methods, study design, threshold selection and particularly blinding of the reference standard to the
index test result. Applicability concerns were almost universally high for participants and index test, due to unrepresentative
samples and the use of image-based OCT interpretation undertaken remotely from study participants. Limited information
was provided regarding the qualifications of the clinicians undertaking and interpreting the tests. The final diagnoses were
established by histology in all studies; however, reference standard interpretation was poorly described.
For the detection of melanoma, a paucity of studies, small sample sizes, and differences in the tests make summary
statements regarding accuracy impossible. Conventional OCT using a data driven threshold in a sample with a high prior
history of melanoma (61%) produced a sensitivity of 89% (95% CI: 52, 100%) and specificity 61% (95% CI: 42, 78%);
however, low resolution was reported as problematic. High definition OCT using a scoring system based on OCT
characteristics misclassified the two included melanoma in situ lesions as OCT negative, leading to a sensitivity of 74% (95%
CI: 54, 89%) and specificity of 92% (95% CI: 83, 97%) for the detection of melanoma or intraepidermal melanocytic variants.
No data were found that compared OCT to standard diagnostic practice for the detection of melanoma.
For the detection of BCC, two studies evaluated observer diagnosis with conventional OCT using the same diagnostic
criteria, in similar populations of participants. Meta-analysis of the 346 lesions resulted in pooled sensitivity of 95% (95% CI:
91, 97%) and specificity 77% (95% CI: 69, 83%). In both studies, OCT was found to be statistically significantly more
sensitive and more specific compared to visual inspection alone (sensitivity 15% higher and specificity 40% higher) and to
visual inspection combined with dermoscopy (sensitivity 9% higher and specificity 22% higher). The Summary of findings
table 1 translates these estimates to a hypothetical cohort of 1000 lesions at the mean prevalence of BCC of 60%. A
sensitivity for OCT of 95% would miss 31 BCCs; a reduction from those that would be missed by using visual inspection
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alone in these lesions of 91 and a reduction from those that would be missed by visual inspection and dermoscopy of 53
BCCs. A specificity of 77% for OCT would result in 93 false positive results; a reduction in unnecessary excisions of 159
compared to using visual inspection alone and of 87 compared to using visual inspection and dermoscopy. Both studies
analysed clinically challenging 'pink' lesions; however, BCC prevalence was very high.
One further study which developed an OCT score (Berlin score) to determine the presence of BCC reported similar
sensitivity and specificity in at least one threshold but it is unclear whether these results would be reproducible. Producing
the only evidence for the detection of cSCC, this study suggests that OCT is poor in its ability to discriminate between BCC
and cSCC when the 'Berlin score' is used. However, the study included few cSCC cases that were retrospectively selected
as 'controls' against the detection of BCC cases, and so is at high risk of having produced biased results. No studies
evaluated high definition OCT technology for the detection and discrimination of keratinocyte skin cancers.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure was planned to allow test accuracy in different study populations to be estimated
and a detailed and replicable analysis of methodologic quality was undertaken.
The main concerns for the review regard the clinical applicability of study findings to a normal practice setting, both
in terms of using more highly selected study populations than are encountered in practice and commonly
interpretating OCT scans remotely from the patient. While OCT could be used in clinical practice to examine
several lesions in a single patient, studies that did so were downgraded in quality appraisal due to the potential bias
introduced by including patients with many lesions (Appendix 4). This was compounded by poor reporting of study conduct,
especially with regard to the reference standard and lack of clear pre-specification of the diagnostic threshold for test
positivity, The inability of the ‘Berlin score’ to differentiate BCC from cSCC and the lack of inclusion of cSCC lesions in the
two studies of observer diagnosis without the aid of the score raises questions over the ability of observers to discriminate
between these lesion types using OCT. Furthermore, no study reported the presence or absence of index test failures, for
example due to inadequate imaging quality or inaccessibility of lesions, and so it is unclear how frequently one would
encounter uninterpretable scans when OCT is used in clinical practice.
Many of the studies excluded from this review were derivation studies or assessed the accuracy of individual OCT
characteristics rather than the overall ability of the test to diagnose a particular skin cancer. This is indicative of the relatively
novel nature of the test and its application to skin cancer diagnosis.
Applicability of findings to the review question
The data included in this review are unlikely to be generally applicable to the clinical setting. Narrow definitions of the eligible
study populations, high disease prevalence, the use of remote image-based test interpretation, and lack of description of the
reference standards used may restrict applicability and transferability of results in practice.
Authors' conclusions 
Implications for practice 
Insufficient data are available to determine the accuracy of OCT for the detection of melanoma or cSCC. For the detection of
BCC, initial data on OCT shows potential increased sensitivity and specificity compared with visual inspection and
dermoscopy; however, the small number of studies and varying methodological quality means that no implications to guide
clinical practice can currently be drawn.
Implications for research 
Further prospective evaluation of optical coherence tomography is warranted in populations with a clinical suspicion of
melanoma, and in populations with a clinical suspicion of keratinocyte skin cancer. For melanoma, these studies should
evaluate HD OCT in comparison to visual inspection and dermoscopy alone, in a standard healthcare setting and with a
clearly defined and representative population of participants with a range of different lesion types to whom study results can
be applied in practice. For a full and proper evaluation of the ability of OCT to detect keratinocyte skin cancers, similar
comparisons should recruit study populations that include sufficient numbers of participants with suspected BCC and cSCC
in order to assess whether the test is able to discriminate adequately between the different forms of skin cancer.
Given that RCM is likely the closest direct ‘competitor’ test to OCT, a comparison with RCM in lesions that are equivocal
following visual inspection and dermoscopy may also be warranted.
The clinical pathway, or referral process, for study eligibility must be clearly described in order to establish the
participant groups to whom study results can be applied in practice. A multi-centred approach would allow
confirmation that results are replicable across centres and that the technology can be implemented across a health
service. Prospective recruitment of a consecutive series of participants, with test interpretation blinded to the
reference standard diagnosis and using pre-specified and clearly defined diagnostic thresholds for determining test
positivity, are easily achieved. In order to be generalisable to clinical practice, studies should perform OCT scans
within the clinical pathway, with interpretation made in the presence of patients and by clinicians experienced with
skin cancer diagnosis and OCT. Points-based ‘rules’ to assist diagnosis require proper validation in an appropriate
clinical setting and would allow a standardised approach to diagnosis. Clear identification of the qualifications and
level of observer training and experience needed to achieve good results is also required. Systematic follow-up of
non-excised lesions avoids over-reliance on a histological reference standard and allows results to be more
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generalisable to routine practice. Any future research study needs to be clear about the diagnostic pathway followed
by study participants prior to study enrolment, and reporting should conform to the updated Standards for Reporting
of Diagnostic Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
Due to the small number of studies available, a single review has been produced that evaluates the accuracy of OCT in all
skin cancers; this replaces the two reviews intended in the protocols to address cutaneous melanoma and keratinocyte
cancers.
For the detection of melanomas, primary objectives and primary target condition have been changed from detection of
cutaneous invasive melanoma alone, to the detection of cutaneous invasive melanoma and intraepidermal melanocytic
variants, as the latter is more clinically relevant to the practicing clinician. These are reported alongside the original primary
objectives and primary target conditions for the review of keratinocyte cancers. The detection of the target condition of
invasive melanoma alone has instead been included as a secondary objective.
Inclusion criteria amended to remove inclusion of participants: "at high risk of developing melanoma, including those with a
family history or previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or genetic cancer
syndromes" and “at high risk of developing BCC or cSCC, including those with a family history or previous history of skin
cancer or genetic cancer syndromes, such as basal cell naevus (Gorlin) syndrome” as these are not target populations for
OCT use.
Studies using cross-validation, such as ’leave-one-out’ cross-validation, were excluded rather than included as these
methods are not sufficiently robust and are likely to produce unrealistic estimates of test accuracy. To improve clarity of
methods, this text from the protocol: “We will include studies developing new algorithms or methods of diagnosis (i.e.
derivation studies) if they use a separate independent ’test set’ of participants or images to evaluate the new approach. We
will also include studies using other forms of cross validation, such as ‘leave-one-out’ cross-validation ( Efron 1983 ). We
will note for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g. the
presence or absence of a pigment network or detection of asymmetry.” has been replaced with: “All established algorithms or
checklists to assist diagnosis were included. Studies developing new algorithms or methods of diagnosis (i.e. derivation
studies) were included if they used a separate independent 'test set' of participants or images to evaluate the new approach.
Studies that did not report data for a separate test set of patients or images were included only if the lesion characteristics
investigated had previously been suggested as associated with melanoma, BCC, or with cSCC, and the study reported
accuracy based on the presence or absence of particular combinations of characteristics. Studies using a statistical model to
produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate test set were excluded.
Studies using cross-validation approaches such as 'leave-one-out' cross-validation ( Efron 1983 ) were excluded.”
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic.
Due to lack of data, we could not perform the following analyses: estimation of accuracy in primary presentation populations,
restriction to analysis of per patient data, comparison of accuracy using diagnosis of stored images (image–based) with
in–person diagnosis, or sensitivity analyses.
We planned three additional heterogeneity investigations relating to population characteristics than those listed in the
protocol (Patient population: primary/secondary/specialist unit; Lesion type: any pigmented/melanocytic; Inclusion of multiple
lesions per participant), however we could not perform these investigations due to insufficient data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Gambichler 2015
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: Germany
Funding: Agfa Healthcare
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients scheduled for melanocytic skin
lesion excision because of cosmetic reasons or suspicion of
CM
Setting: Secondary (Dermato–oncology)
Prior testing: Clinical inspection + dermoscopy
Exclusion criteria: Presence of frank ulceration, marked
hyperkeratosis, histopath confirmation of non–melanocytic
skin lesion
Sample size (patients): No. eligible: NR; No. included: 64
Sample size (lesions): No. eligible: NR; No. included: 93
Participant characteristics: None reported
Lesion characteristics: Mean Breslow thickness of correctly
identified melanoma (all invasive) 1.2 (SD 1.1mm); n=20.
Mean Breslow thickness of missed melanoma (false
negatives) 0.29 (SD 0.23mm) for 5 invasive MM, plus
melanoma in situ
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple lesions?No
Are there concerns that the included patients and setting do
not match the review question? High
Index Test
Index tests
Optical Coherence Tomography - High definition (Skintell; Agfa, Belgium); resolution 3μm lateral by
5μm axial; tissue penetration 570μm; centre wavelength 1300nm; the 3D images of the scans showing
the best quality (i.e. no artefacts) were chosen.
Diagnostic threshold: New scoring system based on previously described micromorphological
HD-OCT correlates of melanocytic skin lesions (Boone 2014; Picard 2013) and from RCM (Segura
2009) and conventional OCT studies (Gambichler 2007); A score ≥ -1 indicated melanoma, a score ≥
-1.5 indicated benign melanocytic skin lesion, i.e. melanoma present if score ≥-1 and < -1.5.
Method of diagnosis: Image-based
Prior test data available: None; blinded to clinical exam and dermoscopy
Diagnosis based on: Single (n = 1)
Observer qualifications: NR; presumed dermatologist
Experience in practice: NR
Experience with index test: High; described as "OCT-experienced investigator"
Any other detail: OCT scoring based on "predominant presence of the following risk (+) and/or
protective (-) features ... (i) HD-OCT en-face mode - typical basal cells/clusters (-1), edged papillae
(-1), honeycomb/cobblestone pattern (-1), large roundish pagetoid cells (+1), atypical cell clusters in
the dermoepidermal junction (DEJ) (+1), totally disarranged epidermal/ dermal pattern (+1); (ii) HD-
OCT slice mode - clearly demarcated DEJ (-0.5), finger-shaped elongated rete ridges (-0.5), bright
bizarre dermal horizontal streaks (+0.5), large vertical icicle- shaped structures (+0.5). The total score
is the sum of the aforementioned sub-scores for the various particular criteria."
Optical coherence tomography
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclearrisk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology alone
Details: Lesions completely excised and processed for routine
haematoxylin and eosin staining, plus immunohistochemistry
for S100 and MART/ Melan-A.
Disease positive: 27; Disease negative: 66
Target condition (Final diagnoses): 
Invasive melanoma: 25; Melanoma in situ: 2
Benign nevi: 66 (23 compound naevi, 20 junctional naevi, 10
dermal naevi, 9 dysplastic naevi, 2 nevoid
lentigo and 2 blue naevi)
Is the reference standards likely to correctly classify the
target condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? (Does not contribute to
Risk of Bias judgement)
Unclear
Could the reference standard, its conduct, or its
interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Consecutive; "after HD-OCT assessments, the
tumours were completely excised"
Interval between index tests: N/A
Exclusions: None reported
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Markowitz 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection not reported
Country USA
Funding: study was sponsored by
Michelson Diagnostics
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients with clinically
challenging pink lesions on the head or neck and
that were suspicious for basal cell carcinoma and
therefore to be biopsied to rule BCC in or out; also
required to be eligible for Mohs surgery; maximum of
three lesions per patient
Setting: Secondary (general dermatology)
Prior testing: Clinical or dermoscopic suspicion of
malignancy; decision to perform diagnostic biopsy
was made following clinical, dermoscopic and OCT
evaluation
Setting for prior testing: Secondary (general
dermatology)
Exclusion criteria: Previous history of skin cancer/
prior treatment at site; history of evidence of
metastases, topical actinic therapy within 8 weeks
prior to evaluation, other skin conditions within lesion
Sample size (patients): No. included: 100
Sample size (lesions): No. included: 115
Participant characteristics: None reported
Lesion characteristics: All head and neck
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Observer diagnosis of BCC; clinically challenging lesions defined as "lesions that
did not have the usual characteristics of BCC, such as ulceration, bleeding, crusting, isolated pink
scaly patches, or pearly papules"; also took into account patient’s clinical history of a nonhealing area
of concern or the clinician’s inability to rule out BCC"
Diagnosis based on: Unclear; likely in clinic diagnoses (n=NR)
Observer qualifications: Not described; likely dermatologist
Experience in practice: Not described
Experience with index test: Not described
Dermoscopy: 2 step algorithm referenced to Marghoob 2010 and Malvehy 2002.
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Dermoscopic features consistent with BCC: arborized vessels, pink white shiny
background, blue/grey ovoid nests, ash leaf pattern, dot-globular-like pattern, spoke wheel, and
crystalline-like structures
Test observers as described for Visual Inspection (above)
OCT: No algorithm; - Multi-beam swept-source frequency domain (VivoSight; Michelson Diagnostics,
UK); resolution axial 10μm, lateral 7.5μm; tissue penetration 2000μm; centre wavelength 1305nm;
“multi-1” setting automatically provided 60 lateral scans of 6mm length every 100μm.
Method of diagnosis: Image-based; OCT scans obtained at time of visual inspection and dermoscopic
diagnoses and read within a week of the diagnostic biopsy
Prior test data: Unclear; clinical and dermoscopic images obtained but not clear whether provided to
OCT interpreter
Diagnostic threshold: Observer diagnosis based on features described in previous studies (Ulrich
2015; Wahrlich 2015; Maier 2013): "epidermis was analysed for protrusions into the dermis with
shadowing; the epidermal-dermal junction for lack of definition or rupturing; and the dermis for signal-
poor ovoid structures, dark rims, ovoid structures with bright centres, dilated vessels, black areas or
cysts, bright stroma, and/or small ovoid signal-poor structures (“fish shoal”)"
Test observers: Not described
Optical coherence tomography
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Details: None reported
Disease positive: 70 BCC; Disease
negative: 45
Target condition (Final diagnoses) 
BCC: 70; 'Benign' diagnoses: 45 (not
further described)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? (Does not contribute to Risk of Bias judgement) Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: Appears
consecutive; Figure 2 describes the OCT
scans undertaken at the time of clinical
examination and dermoscopy; diagnostic
biopsy is then performed and the "OCT scan is
read within a week, prior to obtaining the
results of the diagnostic biopsy"
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
Time interval between index test(s):
Consecutive; clinical, dermoscopic and OCT
images taken at the same time; clinical and
dermoscopic diagnoses made at the time of
taking the images while OCT scans were read
within a week.
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? No
Was the interval between application of the index tests less than one
month? Yes
Are there any concerns that the test comparison could have introduced
bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear
Are there concerns that the test comparison differs from the review question? Unclear
Notes
Notes -
 
Ulrich 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection April 2013 to March
2014
Country Germany
Funding: study was funded by Michelson
Diagnostics Ltd (MDL)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with non-pigmented pink lesions with
clinical suspicion of BCC requiring biopsy for diagnostic
confirmation. Pink lesions defined as clinically unclear
erythematous papule or plaque; either reddish macules,
patches or small papules with or without scale. [only lesions
with histology included]
Setting: Multicentre study; authors' institutions included
Dermatology departments (n=4) and private dermatology
offices (n=3)
Prior testing: Inclusion was based on clinical assessment
alone, without the assistance of dermoscopy
Setting for prior testing: Unspecified
Exclusion criteria: Unequivocal appearance/diagnosis - Lesions
with the typical clinical appearance of BCC on clinical
examination (such as the presence of a pearly border, central
ulceration and obvious telangiectasias), as well as pigmented
lesions, were excluded from the protocol. Patients with
unstable or uncontrolled clinically significant medical conditions
were excluded. Lesions with missing histology also excluded
(n=21)
Sample size (patients): No. eligible: 164; No. included: 155
Sample size (lesions): No. eligible: 256; No. included: 235
(different sets of 231 lesions were available for each test)
Participant characteristics: Median age: 70y (33-90y)
Lesion characteristics Head/Neck: 41%; Upper body 48.8%
Are the included patients and chosen study setting
appropriate? No
Did the study avoid including participants with multiple
lesions? No
Are there concerns that the included patients and setting do
not match the review question? High
Index Test
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Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in person diagnosis
Diagnostic threshold: Observer diagnosis of BCC; pink or red lesions that could be either macules,
patches or small papules with or without scale.
Diagnosis based on: Single observer; (n=NR; 6 centres participated)
Observer qualifications: but probably dermatologists given authors institutions
Experience in practice: Not described
Experience with index test: Not described
Dermoscopy; No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Observer diagnosis; "A scattered vascular global pattern with loose haphazard
distribution. Shiny white to red structures with or without chrysalis-like structures. Small fine
telangiectasias appearing as fine, kinked vessels of small calibre, with length < 1 mm in superficial
BCC and larger arborizing vessels in more invasive BCC (nodular/infiltrative)"; referenced to
Marghoob 2012.
Test observers as described for Visual Inspection (above)
Any other detail: After clinical examination dermoscopy was carried out using a Dermlite ProHr (3Gen
Inc., San Juan Capistrano, CA,U.S.A.), attached to a Sony Cybershot DSC-W710 camera (Sony,
Tokyo, Japan) (supplied by MDL). As polarized light was used, no preparation of the area under
examination was necessary
OCT: No algorithm; Multi-beam swept-source frequency domain; Vivosight (MDL); resolution axial
10μm, lateral 7.5μm; tissue penetration 2000μm; centre wavelength 1305nm; the function ‘multi-1’
setting automatically provided 60 lateral scans of 6mm length every 100 um.
Method of diagnosis: In person; OCT images were assessed following dermoscopy by naked eye for
features affecting the epidermis, the dermoepidermal junction and the dermis.
Prior test data available: Clinical exam and dermoscopy
Diagnostic threshold: Observer diagnosis; based on "Epidermis: protrusions into the dermis with
shadowing; dermoepidermal junction: lack of definition or rupturing; and dermis: signal-poor ovoid
structures, dark rims, ovoid structures with bright centres, dilated vessels, black areas or cysts, bright
stroma and small ovoid signal-poor structures (‘fish shoal’)." Paper cites Boone 2012 as having been
published since the study was designed.
Observers: As above. All centres described as regular users of OCT, with at least 3 months of
practical experience with the device. Nonetheless, all centres received training before participating in
the study.
Optical coherence tomography
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Visual inspection
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Dermoscopy
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Lowconcern
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Reference standard Histological diagnosis
alone
Details: a biopsy or excision of the lesion was
taken
Disease positive: 141; Disease negative: 94
Target condition (Final diagnoses) 
BCC: 141
'Benign' diagnoses: 94 (32 actinic keratosis, 17
Bowen's disease, 6 seborrhoeic keratoses, 6
inflammatory diseases (psoriasis,eczema etc),
34 other including sebaceous hyperplasia,
dermal naevus, microcystic adrexal carcinoma
NB: different sets of 231 lesions were recorded
for each test, therefore the number diseased
per 2x2 varies
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? (Does not contribute to Risk of Bias judgement) Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: Histology was missing for
21 lesions, and one case was found to have a
combination of both BCC and SK or AK, leaving
235 lesions for analysis in the ITT group
Time interval to reference test: consecutively
done after index test "All diagnostic steps had to
be completed before histological confirmation
was made."
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the
interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Time interval between index test(s):
Consecutive
Was each index test result interpreted without knowledge of the results of
other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes
Are there concerns that the test comparison differs from the review question? Lowconcern
Notes
Notes -
 
Wahrlich 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Retrospective
Period of data collection: Sept 2011 to Jun 2012
Country: Germany
Funding: None; OCT device provided by
Michelson Diagnostics
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Participants with non-melanoma
skin cancer including BCC or other skin lesions;
phase 1 of study excluded as student observers
Setting: Secondary (Dermatology)
Prior testing: Unclear
Exclusion criteria: pre-operated or ulcerated lesions.
Sample size (patients): No. eligible: NR; No.
included: 50
Sample size (lesions): No. eligible: 50; No.
included: 50
Participant characteristics: mean age 62.8y; 46%
male
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
OCT: 'Berlin score', developed by authors 'prior to the start of the study' based on data from other
study groups; Multi-beam swept-source frequency domain; Vivosight (MDL); resolution axial 10μm,
lateral 7.5μm; tissue penetration 2000μm; centre wavelength 1305nm; performed using free-run and
multi-slice functions on an area of 6 x 6 x 2 mm. Affected areas were shaved (hairy areas) or pre-
treated with Sellotape (scaly lesions) as required
Diagnostic threshold: Two thresholds assessed, Berlin score <= 8 (T1 limit) and of <= 12 (T2 limit)
Method of diagnosis: Unclear
Prior test data available: Unclear; appears that following histological diagnosis the histologist then
retrospectively examined the OCT images
Diagnosis based on: Single (n = 1)
Observer qualifications: Dermatopathologist; described as "dermatological
specialist/dermatopathologist and expert familiar with OCT
Experience in practice: High
Experience with index test: High
Other detail: BCC features subdivided into major (dark borders underneath the tumour,
hyporeflective nests and ovoid structures) and minor criteria (disruption of
dermal–epidermal junction (DEJ) and cysts). Presence of feature classed between 0
(absent) and 3 (clearly recognizable structure); visible (2) and less visible (1) structures
could not clearly be allocated. Criteria were added to a cumulative score with a maximum
of 24 points. Binary logistic regression identified limit values (T1,T2) to differentiate BCC
from ‘others’ using phase 1 of the study (100 BCC and 30 'other' skin diseases; using
student observers). Main diagnostic features based on already existing data of other study
groups (Khandwala 2010; Mogensen 2009; Sabban 2004; Vogt 2003; Zhao 2008).
Optical coherence tomography
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? No
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology alone
Details: Biopsy or excision
Disease positive: 29; Disease negative: 21
Target condition (Final diagnoses): 
BCC 29; cSCC 9
Bowen's disease 7; Actinic keratosis 5
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? (Does not contribute to Risk of Bias judgement) Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Consecutive; OCT described as followed by
excision or biopsy
Exclusions: Discussion reports exclusion of 3
participants due to anatomical position,
different scan 'heights' and shadow artefacts.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
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Wessels 2015
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Nov 2011 – April
2012
Country: Netherlands
Funding: None declared
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Consecutive patients with
pigmented (melanocytic) lesions with clinical
suspicion of melanoma during routine skin cancer
screening, from whom an excision had to be taken in
the outpatient clinic of the Netherlands Cancer
Institute in Amsterdam.
Setting: Secondary; outpatient clinic
Prior testing: Clinical assessment during routine skin
cancer screening
Exclusion criteria: None reported
Sample size (patients): No. eligible: NR; No.
included: 33
Sample size (lesions): No. eligible: NR; No.
included: 40
Participant characteristics: Mean age 46y (SD 16);
42% Male; History of melanoma (20, 61%);
Lesion characteristics: All lesions rated as clinically
suspicious on naked eye and 19 also had
dermoscopic suspicion; Lesion site - Trunk and
Neck (28, 70%), arms and legs (12, 30%);
Fitzpatrick type 1 (2,6%), type 2 (15,46%), type 3
(15,46%), type 4 (1,3%). Mean attenuation
coefficient of benign lesions was 5.49 mm-1 and
4.28 mm-1 for melanomas.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
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Index tests
OCT: No algorithm; Swept-source OCT (Santec Inner Vision 2000); resolution axial 10μm, lateral
20μm; tissue penetration 2000μm; centre wavelength 1300nm; for each lesion 5 2D and one 3D OCT
scans were recorded, plus 5 2D scans from healthy skin next to the lesion. Attenuation coefficient
could not be identified in 20 2D OCT scans due to thin layer thickness.
Diagnostic threshold: Investigated accuracy of two morphological features on 3D scans (absence of
clear dermoepidermal junction and no lower boundary of lesion visible) and attenuation coefficient
based on 2D scans 5.4mm-1 (optimal threshold estimated via Youden index)
Method of diagnosis: Image-based
Prior test data available: Unclear; "All scans were stored to be analysed at a later date by one
investigator (RW) blinded for the pathology report."
Diagnosis based on: Single (n=1)
Observer qualifications: Unclear; investigator institution Dept of Surgery
Experience in practice: Not described
Experience with index test: Not described
Other detail: epidermal layer thickness and the attenuation coefficient (μoct mm-1) were
measured. "The attenuation coefficient is the decrease in light intensity per millimetre;
measurement was performed as described before (Faber 2004) using custom written software
(LabVIEW 2011; National Instruments, Austin, TX, USA).
Optical coherence tomography
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted
without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histology alone
Details: Excision; All stained sections were
reviewed by one pathologist.
Disease positive: 9; Disease negative: 31
Target condition (Final diagnoses): 
Invasive melanoma 7; Melanoma in situ 2
Benign nevi: 31 (24 compound nevi, 5
dysplastic nevi)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? (Does not contribute to Risk of Bias judgement) Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Consecutive; "After OCT-imaging, excision
was performed"
Exclusions: None reported
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign
appearing lesions, was there a minimum follow-up following application of
index test(s) of at least: 3 months for melanoma or cSCC or 6 months for
BCC?
If more than one algorithm was evaluated for the same test, was the interval
between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes -
 
Footnotes
AK - actinic keratosis; BCC - basal cell carcinoma; BD - Bowens disease; CM - cutaneous melanoma; cSCC - cutaneous
squamous cell carcinoma; DEJ - dermoepidermal junction; HD-OCT - high definition optical coherence tomography; ITT -
intention-to-test; MM - malignant melanoma; N/A - not applicable; NR - not reported; NS - not specified; OCT - optical
coherence tomography; SD - standard deviation; SK - seborrhoeic keratosis.
Characteristics of excluded studies 
Alawi 2013
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Reason for exclusion EXCLUDE on index test
OCT used to determine surgical margins
 
Bechara 2004
Reason for exclusion EXCLUDE on sample size
only 3 BCCs
EXCLUDE if individual lesion characteristics
 
Boone 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Boone 2015
Reason for exclusion EXCLUDE on study population
includes healthy volunteers; also pre-selected AK and SCC
EXCLUDE if derivation study
study developed a diagnostic algorithm for HD-OCT (no independent test population)
 
Boone 2015a
Reason for exclusion EXCLUDE if derivation study
EXCLUDE on 2x2 data
 
Boone 2016
Reason for exclusion EXCLUDE if derivation study
appears to be first study assessing optical proporties of HD-OCT rather than dx by
morphological characteristics
 
Brudermanns 2008
Reason for exclusion EXCLUDE not a primary study
Comment on Gambichler 2007
 
Calin 2013
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Coleman 2013
Reason for exclusion EXCLUDE on study population
no results for benign lesions
 
Cunha 2011
Reason for exclusion EXCLUDE on study population
all BCC cases (no benign lesions)
 
de Boer 2016
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Reason for exclusion EXCLUDE not a primary study
systematic review (not addressing OCT)
 
de Giorgi, 2005
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
 
Evans 2014
Reason for exclusion EXCLUDE not a primary study
Editorial review
 
Forsea 2010
Reason for exclusion EXCLUDE on sample size
EXCLUDE if derivation study
 
Gambichler 2007
Reason for exclusion EXCLUDE if derivation study First study of OCT in skin cancer; Looking at features of
OCT and comparing with histology.
EXCLUDE on 2x2 data not enough data to populate 2x2 table
 
Gambichler 2014
Reason for exclusion EXCLUDE on study population
BCCs only included
 
Gambichler 2015a
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
 
Hinz 2011
Reason for exclusion EXCLUDE on target condition
assesses tumour thickness only
 
Hussain 2015
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Hussain 2016
Reason for exclusion EXCLUDE on study population
Patients undergoing FU for recurrent BCC
EXCLUDE on target condition
recurrent BCC
 
Jorgensen 2008
#165e Optical coherence tomography for the diagnosis of skin cancer in adults
36 / 95
Reason for exclusion EXCLUDE on index test
Machine learning OCT 
 
Maier 2013
Reason for exclusion EXCLUDE on study population– BCCs only included (no disease negative included)
 
Marneffe 2016
Reason for exclusion EXCLUDE on study population
AK - SCC - normal skin
 
Meyer 2014
Reason for exclusion EXCLUDE on target condition
detection of lesion thickness only
 
Mogensen 2009
Reason for exclusion EXCLUDE on study population
Differentiating NMSC from normal skin
EXCLUDE on reference standard
not clearly reported; described as 'clinically diagnosed' 
 
Mogensen 2009a
Reason for exclusion EXCLUDE not a primary study
review/opinion paper
 
Mogensen 2009b
Reason for exclusion EXCLUDE on target condition
precision of tumour size measurements
 
Moraes 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Olmedo 2006
Reason for exclusion EXCLUDE on study population - BCCs only included (no disease negative included)
 
Olsen 2015
Reason for exclusion EXCLUDE not a primary study
systematic review
 
Picard 2013
Reason for exclusion EXCLUDE not a primary study
case report
 
Reggiani 2015
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Reason for exclusion EXCLUDE not a primary study
systematic review
 
Strasswimmer 2004
Reason for exclusion EXCLUDE on sample size
2 cases presented
EXCLUDE if derivation study
 
Ulrich 2014
Reason for exclusion EXCLUDE conference abstract
included full paper ( Ulrich 2015 )
 
Welzel 1998
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; preliminary study of OCT
 
Wessels 2013
Reason for exclusion EXCLUDE conference abstract
included full paper ( Wessels 2015 )
 
Zakharov 2014
Reason for exclusion EXCLUDE conference abstract
 
Zakharov 2015
Reason for exclusion EXCLUDE on index test
ex-vivo diagnosis not relevant to the review
 
Footnotes
Characteristics of studies awaiting classification 
Cheng 2016
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Patient Sampling Consecutive group of patients at moderate to very high risk of melanoma presenting to
Melanoma Institute Australia from April 2014 - March 2015 with possible sBCC based
on clinical and dermoscopic findings.
 
Patient characteristics and setting 168 lesons; 52% were sBCC, 26% were other BCC variants and the remaining lesions
were actinic keratosis, squamous cell carcinoma in situ, other benign inflammatory
processes and two other malignant tumours.
 
Index tests Visual examination, dermoscopy, optical coherence tomography
 
Target condition and reference
standard(s)
BCC, histology (punch biopsy)
 
Flow and timing Biopsy performed immediately after OCT scanning
 
Comparative No
 
Notes Comparison of 3 observers with varying levels of OCT experience. Confidence in the
diagnosis also recorded
 
Olsen 2016
Patient Sampling Retrospective study of image bank from scans performed 2010 - 2015.
 
Patient characteristics and setting 142 Good quality OCT images of BCC, AK and normal skin (good quality defined as:
minimal shadowing artefacts from hairs, hyperkeratosis and crustae)
 
Index tests OCT
 
Target condition and reference
standard(s)
BCC, Histology
 
Flow and timing Not reported
 
Comparative No
 
Notes Published August 2016 but not id in update search; awaiting author communication to
allow inclusion (contacted 07-06-17)
 
Footnotes
AK - actinic keratosis; BCC - basal cell carcinoma; OCT - optical coherence tomography.
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Summary of Findings
Question What is the diagnostic accuracy of optical coherence tomography for the diagnosis of skin cancer in
adults?
Population: Adults with skin lesions suspicious for melanoma (2/5) or for BCC (3/5). No studies recruited sufficient
numbers of cases of cSCC for inclusion.
Prior testing and
prevalence:
All studies included lesions selected for excision or biopsy. There was some requirement for clinical
suspicion of malignancy (1/2 in melanoma) and for recruitment of only clinically challenging lesions (2/3 in
BCC). The prevalence of melanoma was 23 to 27%; prevalence of BCC ranged from 58 to 61%.
Settings: Secondary care and specialist cancer clinics.
Target
condition(s):
Invasive melanoma and atypical intraepidermal melanocytic variants (2); basal cell carcinoma (3).
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Question What is the diagnostic accuracy of optical coherence tomography for the diagnosis of skin cancer in
adults?
Index test: Conventional and high density optical coherence tomography (OCT); diagnostic thresholds based on
subjective assessment of OCT features with (2) and without (2) associated scoring, and quantitative
assessment of attenuation (1).
Reference
standard:
Histology
Action: If accurate, positive results of OCT could help to appropriately select lesions for excision and reduce
multiple biopsies in those with suspected BCC.
Limitations
Risk of bias: Patient selection methods unclear (3/5) due to lack of description of recruitment methods (2) or study
design (1). High risk of bias for the index test due to lack of blinding (1/5) and clearly (1/5) or possibly (1/5)
data driven thresholds. Reference standard blinding was not described (5/5). Timing of index and
reference standards was not reported. Exclusions due to test failures were not reported (3/5) or their final
diagnoses were not described (1/5). Low risk of bias for flow and timing apart from exclusions due to
missing histology (1/5) and failure to adequately image lesions (1/5). No other index test failures
mentioned.
Applicability of
evidence to
question:
High (3/5) or unclear (1/5) concerns about applicability of participants due to unrepresentative participant
samples or multiple lesions per participant (1/5). High concerns about applicability of index test due to
image-based diagnosis (4/5) with blinding to all other clinical information (1/5) or unclear information
provided to test observers (2/5). Reference standard interpretation by experienced histopathologists not
described (4/5).
Quantity of evidence
Number of
studies
5  
Total
participants
with test resultsa
402  
Total lesions with test
resultsa
529 Total
melanoma
lesions
36
Total BCC
lesions
240
Total cSCC
lesions
9
Detection of invasive melanoma and atypical intraepidermal melanocytic variants
 
Number of studies
Total lesions
with test results Total lesions with melanoma
2 133 36 (32 invasive, 4 melanoma in situ)
Findings
Two studies evaluated invasive melanoma and melanoma in situ:
Conventional OCT at an attenuation coefficient of 5.4mm-1: sensitivity 89% (95% CI: 52, 100%) and
specificity 61% (95% CI: 42, 78%); (1/2)
HD OCT sensitivity 74% (95% CI: 54, 89%) and specificity 92% (95% CI: 83, 97%) using scoring
system based on OCT characteristics (1/2); both melanoma in situ lesions misclassified as negative
on OCT.
Detection of BCC [pooled analysisb]
 
Number of studies
Total lesions
with test results Total lesions with BCC
3 [2] 396 [346] 237 [208]
Pooled analyses Numbers observed in a cohort of 1000 lesions being tested (atmean prevalence 60%)c
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Question What is the diagnostic accuracy of optical coherence tomography for the diagnosis of skin cancer in
adults?
2 studies of
observer diagnosis
with VI alone, VI
plus dermoscopy,
and with OCT
(total n = 346;
melanoma n =
208) Sensitivity (95% CI)
Specificity
(95% CI)
True Positive False Positive FalseNegative True Negative
(receive
necessary
excision)
(receive
unnecessary
excision)
(do not
receive
required
excision)
(appropriately not
excised)
VI alone:
80%
(55,
93)
37% (24, 52) 478 252 122 148
VI plus 
dermoscopy:
86%
(76,
92)
55% (46, 63)
516
(↑38)
180
(↓72)
84
(↓38)
220
(↑72)
OCT:
95%
(91,
97)
77% (69, 83)
569
(↑53)
93
(↓87)
31
(↓53)
307
(↑87)
Findings
 
Pooled studies - results consistent between studies; conducted in clinically equivocal populations.
Other studies (n = 1) - Similar results for OCT obtained using Berlin score at ≥ 8 (sensitivity 97% (95% CI:
82, 100%) and specificity 76% (95% CI: 53, 92%)) with lower sensitivity (66% (95% CI: 46, 82%)) and
higher specificity (86% (95% CI: 64, 97%)) at the higher score of ≥ 12. Unclear whether this would be
replicated in usual practice setting.
Detection of cSCC
Findings
One case-control study with 9 cSCCs, total number of lesions = 50:
Poor sensitivity for OCT obtained using Berlin score at ≥ 8 (sensitivity 56% (95% CI: 21, 86%) and
specificity 100% (95% CI: 91, 100%)) with lower sensitivity (33% (95% CI: 7, 70%)) and the same
specificity (100%) at the higher score of ≥ 12. Unclear whether this would be replicated in usual practice
setting.
Footnotes
aAll results use lesions as the unit of analysis
bSquared brackets indicate numbers used in pooled analysis
cNumbers estimated at 25th, 50th (median) and 75% percentiles of basal cell carcinoma prevalence observed across 2
datasets reporting evaluations of OCT added to dermoscopy and visual inspection
BCC - basal cell carcinoma; cSCC - cutaneous squamous cell carcinoma; CI - confidence interval; HD - high definition; OCT
- optical coherence tomography; VI - visual inspection
Additional tables 
1 Glossary of terms
Term Definition
Acantholytic subtypes An uncommon squamous cell carcinoma variant characterised by acantholysis, which is the
marked disruption of intercellular connections and resulting separation of epidermal cells
Arborizing blood vessels Blood vessels in the skin that form a tree-like branching appearance. They can be a sign of
basal cell carcinomas
Atypical honeycombing This pattern arises from variation in size and shape of keratinocytic nuclei and irregular cell
borders of keratinocytes in the spinous-granular epidermal layer. It is a feature of actinic
keratosis and squamous cell carcinoma on optical coherence tomography and on reflective
confocal microscopy examination
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
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Term Definition
Atypical pleomorphic
keratinocytes
Abnormal skin cells of different shapes and sizes, a feature visible on histopathology
Axial resolution Axial resolution describes the ability of an OCT system to distinguish between two points in
space that lie in the direction parallel to the light beam
Basaloid cells Cells in the skin that look like those in epidermal basal layer
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
 
Dermoscopy
Whereby a handheld microscope is used to allow more detailed, magnified, examination of
the skin compared to examination by the naked eye alone
Dermo-epidermal junction The area where the lower part of the epidermis and top layer of the dermis meet
Dermal nests Collections of pigment cells that are bunched together in the dermis
Dermal papilla Small projections of the dermis into the overlying epidermis giving an undulating pattern and
visible as "fingerprints" in hands and feet
Dermis Layer of skin below the epidermis, composed of living tissue and containing blood
capillaries, nerve endings, sweat glands, hair follicles and other structures
Desmoplastic subtypes of
SCC
An aggressive squamous cell carcinoma variant characterised by a proliferation of
fibroblasts and formation of fibrous connective tissue
Electrodessication The use of high frequency electric currents to cut, destroy or cauterise tissue. It is performed
with the use of a fine needle-shaped instrument
Epidermis Outer layer of the skin
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them
as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having
the disease.
Fibrotic septa Excess fibrous connective tissue formation separating other parts of tissue
Grey-blue ovoid nests and
globules
Grey-blue coloured oval shaped areas seen under dermoscopy that may represent basal
cell carcinomas
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Hypertrophic actinic keratosis Precancerous scaly patches of skin that are particularly thickened
Hypoechogenic Displaying lower echogenicity reflecting and appears darker on ultrasonography
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Inflammatory dermatoses Skin conditions where the main disease process is inflammatory, often involving immune
cells, as apposed to malignant or infectious processes. The inflammatory process may be
due to internal or external factors
Interferometry The measurement of waves of light or sound after interference in order to extract information
Interfollicular epidermis The part of the epidermis that lies in between the hair follicles
Junctional nests Collections of pigment cells bunched up around the junction between the epidermis and
dermis
Lateral resolution Lateral resolution describes the ability of an OCT system to distinguish between two points
in space that lie in a perpendicular direction to the light beam
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes
malignant cells but with no invasive growth. May progress to an invasive melanoma
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Term Definition
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream or
the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic activity Relates to the presence of proliferating cells and used as an index of tumour aggressiveness
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Naevus A mole or collection of pigment cells (plural: naevi or nevi)
Nuclear dysplasia and mitoses A histopathological term referring to abnormal nuclei with increased mitotic activity and
nuclear size associated with disordered nuclear dysplasia and mitoses cell growth
Nucleated The presence of a nuclei within a cell, which contain most of the cell's genetic material
Pagetoid cells Abnormal pigment cells that spread upwards through the epidermis
Papillary dermis Also called the 'upper dermis', this is the uppermost layer of the dermis that connects to the
dermal-epidermal junction
Peripheral palisading A histopathological term referring to the wall-like appearance of cells around a central focus
Pleomorphic Variability in size or shape
Polygonal cells Skin cells that appear to have many sides, such as taking up a pentagonal, hexagonal or
octagonal appearance
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis
The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either
at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an
evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Resolution Resolution in an imaging system refers to its ability to distinguish two points in space as
being separate points; resolution is measured in two directions: axial and lateral.
Rete ridges Also called 'epidermal ridges' or 'epidermal pegs', they represent downward projections of
the epidermis into underlying connective tissue
Reticular dermis Also called the 'lower dermis', the reticular dermis is the lower layer of the dermis, located
under the papillary dermis
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Term Definition
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin
lesions) who have that absence of disease correctly identified by the study test
Spindle subtypes of SCC A squamous cell carcinoma variant characterised by poorly differentiated spindle cells
surrounded by collagenous stroma
Spinous-granular layer One of several layers of the epidermis, which is the outermost layer of skin. The nuclei of
keratinocytes, which contain most of the cell's genetic material are found here
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories.
Stratum corneum The outermost layer of the epidermis. This layer is the most superficial layer of skin, which is
composed of flattened skin cells organised like a brick wall. In normal conditions cells are
not nucleated at this layer
Stromal reaction Change in connective tissue microenvironment
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination.
Superficial fine telangiectasia Fine dilated blood vessels of small/varying diameter located in the superficial dermis
Targetoid hair follicles The presence of yellow keratotic follicular plugs surrounded by a white rim on dermoscopy,
more frequently known as 'white circle', which can be a characteristic of squamous cell
carcinoma
Footnotes
2 Description of diagnostic thresholds used by optical coherence tomography for the detection of all target
conditions
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Study Threshold Threshold detail
Melanoma
 
Gambichler
2014
HD-OCT
Score ≥ -1 MM;
score of ≥ -1.5
benign MSL,
based on sum of
sub-scores for
various OCT
characteristics
 
New scoring system based on previously described micromorphological HD-OCT
correlates of melanocytic skin lesions (Boone 2014; Picard 2013) and from RCM (Segura
2009) and conventional OCT studies (Gambichler 2007)
OCT scoring based on "predominant presence of the following risk (+) and/or protective (-)
features ... (i) HD-OCT en-face mode - typical basal cells/clusters (-1), edged papillae (-1),
honeycomb/cobblestone pattern (-1), large roundish pagetoid cells (+1), atypical cell
clusters in the dermoepidermal junction (DEJ) (+1), totally disarranged epidermal/ dermal
pattern (+1); (ii) HD-OCT slice mode - clearly demarcated DEJ (-0.5), finger-shaped
elongated rete ridges (-0.5), bright bizarre dermal horizontal streaks (+0.5), large vertical
icicle- shaped structures (+0.5). The total score is the sum of the aforementioned sub-
scores for the various particular criteria."
 
Wessels
2015
SS-OCT
Attenuation
coefficient 5.4mm-1
 
Based on 2D scans: "The attenuation coefficient is the decrease in light intensity per
millimetre; measurement was performed as described before (Faber 2004) using custom
written software (LabVIEW 2011; National Instruments, Austin, TX, USA).” The optimal
attenuation coefficient of 5.4mm-1 was estimated using Youden’s index.
(Attenuation refers to the loss of signal by scattering and absorption of light; scattering is
caused by the nature of cellular structures, while absorption is caused by skin tissue’s
biochemical composition. The ‘attenuation coefficient (μoct)’ plots OCT signal decay by its
penetration depth. The authors hypothesise that this tracks morphological and physiological
changes in tissue.)
Study also investigated accuracy of two morphological features on 3D scans (absence of
clear dermoepidermal junction and no lower boundary of lesion visible) but these were
excluded from review
BCC
 
Markowitz
2015
SS-OCT
Diagnostic
judgement (BCC
present/absent)
Observer diagnosis was based on features described in previous studies (Maier 2013; 
Ulrich 2015; Wahrlich 2015): "epidermis was analyzed for protrusions into the dermis with
shadowing; the epidermal-dermal junction for lack of definition or rupturing; and the dermis
for signal-poor ovoid structures, dark rims, ovoid structures with bright centers, dilated
vessels, black areas or cysts, bright stroma, and/or small ovoid signal-poor structures ('fish
shoal')"
 
Ulrich 2015
SS-OCT
Diagnostic
judgement (BCC
present/absent)
Observer diagnosis; based on "Epidermis: protrusions into the dermis with shadowing;
dermoepidermal junction: lack of definition or rupturing; and dermis: signal-poor ovoid
structures, dark rims, ovoid structures with bright centres, dilated vessels, black areas or
cysts, bright stroma and small ovoid signal-poor structures ('fish shoal')." Paper cites
Boone 2012’s identification of features for BCC as having been published since the study
was designed.
 
Wahrlich
2015
SS-OCT
1. Berlin score ≥ 8
2. Berlin score ≥
12
BCC features subdivided into major (dark borders underneath the tumour,
hyporeflective nests and ovoid structures) and minor criteria (disruption of
dermal–epidermal junction (DEJ) and cysts). The presence of each feature was
classed between 0 (absent) and 3 (clearly recognizable structure); visible (2)
and less visible (1) structures could not clearly be allocated. Criteria were added
to a cumulative score with a maximum of 24 points. Binary logistic regression
identified limit values (T1,T2) to differentiate BCC from ‘others’ using lesions in
phase 1 of the study (100 BCC and 30 'other' skin diseases; using student
observers). T1 threshold identified as ≥ 8 and T2 ≥ 12. Main diagnostic features
were based on already existing data from other study groups (Khandwala 2010; Mogensen
2009; Sabban 2004; Vogt 2003; Zhao 2008).
Footnotes
BCC - basal cell carcinoma; DEJ - dermoepidermal junction; HD-OCT - high definition optical coherence tomography; MM -
malignant melanoma; OCT - optical coherence tomography; RCM - reflectance confocal miscroscopy; SS-OCT - swept-
source optical coherence tomography.
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Test StudiesParticipants
1 OCT Attenuation coefficient 5.4mm-1 (MM+Mis)1 40
2 HD-OCT Gambichler score ≥ -1 (MM+Mis) 1 93
3 HD-OCT - Gambichler score ≥ -1 (MM) 1 93
4 OCT observer diagnosis (BCC) 2 346
5 VI observer diagnosis (BCC) 2 346
6 Dermoscopy observer diagnosis (BCC) 2 346
7 OCT Berlin score ≥ 8 (BCC) 1 50
8 OCT Berlin score ≥ 12 (BCC) 1 50
9 OCT Berlin score ≥ 8 (cSCC) 1 50
10 OCT Berlin score ≥ 12 (cSCC) 1 50
Figures
Figure 1
Caption
Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right)
Figure 2
Caption
Sample photographs of BCC (left) and cSCC (right)
Figure 3
#165e Optical coherence tomography for the diagnosis of skin cancer in adults
62 / 95
Caption
Swept–source Optical Coherence Tomography scanner (Michelson Diagnostics VivoSight Rx). Copyright © 2017 Rakesh
Patalay: reproduced with permission.
Figure 4
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Caption
OCT image of a 7mm BCC on the cheek showing several BCC cell nests (left hand star is above and to the left of a BCC
nest) and the position of the 2mm margin as drawn with a reflective ink pen (right hand star). The ink pen gives the
appearance of increased reflectivity in the epidermis, and causes a fine vertical linear interference of the OCT signal of the
skin, giving a unique OCT signature. In this case, the interference is also seen to mask the OCT signal from the dermis under
the pen mark. Copyright © 2017 Rakesh Patalay: reproduced with permission.
Figure 5
Caption
OCT image of a nodular BCC showing a basal nest centrally (star). The Dark halo appearance is due to a cleft region fully
encompassing the nest and the presence of peripheral palisading. Copyright © 2018 Michelson Diagnostics / Vivosight
Figure 6
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Caption
Current clinical pathway for people with skin lesions
Figure 7
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Caption
PRISMA flow diagram.
Figure 8
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Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 9
Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 10 (Analysis 1) 
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Caption
Forest plot of threshold data that could not be pooled for the diagnosis of melanoma and atypical intraepidermal melanocytic
variants (MM + Mis), invasive melanoma alone (MM), basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma
(cSCC).
Figure 11 (Analysis 2) 
Caption
Forest plot of tests: Pooled data for the detection of basal cell carcinoma (BCC) using Visual inspection (VI), Dermoscopy,
and optical coherence tomography (OCT).
Figure 12 (Analysis 3) 
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Caption
Summary ROC Plot of studies comparing optical coherence tomography (OCT) and visual inspection (VI) for the detection of
basal cell carcinoma (BCC).
Figure 13 (Analysis 4) 
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Caption
Summary ROC Plot of studies comparing optical coherence tomography (OCT) and dermoscopy for the detection of basal
cell carcinoma (BCC)
Sources of support 
Internal sources
No sources of support provided
External sources
The National Institute for Health Research (NIHR), UK
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
NIHR Systematic Review Programme, UK
Feedback 
Appendices 
1 Current content and structure of the Programme Grant
#165e Optical coherence tomography for the diagnosis of skin cancer in adults
70 / 95
List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
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9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
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55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
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101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
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29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
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75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
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18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
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64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
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110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
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#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
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#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
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#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
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S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
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S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
3 Full text inclusion criteria
The title and abstract screening will lead to the retrieval of a large number of full text journal papers and conference abstracts
from which to populate the four sets of test accuracy reviews and the intervention review. The systematic reviews will largely
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be carried out sequentially, beginning with the reviews of tests for melanoma diagnosis; however, the full text papers need to
be screened at the beginning of the Programme Grant and papers meeting the inclusion criteria tagged accordingly per
review.
The table below summarises the inclusion criteria to be applied; these will be transferred to an Excel spreadsheet or Google
Forms so that pertinent information can be recorded about each eligible study and reasons for exclusion recorded about
each ineligible study.
Criterion Inclusion Exclusion
Study design  
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
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Criterion Inclusion Exclusion
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
4 Quality assessment (based on QUADAS-2)
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants
or images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design clearly not
used
No – if study described as case-control or describes sampling
specific numbers of participants with particular diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions?
lesions not excluded on basis of disagreement
between evaluators
Yes – if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test accuracy, e.g.
where disagreement between evaluators was observed
Unclear – if not clearly reported
 
4) For between-person comparative studies only (i.e.
allocating different tests to different study participants):
A) were the same participant selection criteria used
for those allocated to each test?
B) was the potential for biased allocation between
tests avoided through adequate generation of a
randomised sequence?
C) was the potential for biased allocation between
tests avoided through concealment of allocation prior
to assignment?
For A)
Yes – if same selection criteria were used for each index test,
No – if different selection criteria were used for each index test,
Unclear – if selection criteria per test were not described, N/A –
if only 1 index test was evaluated or all participants received all
tests
For B)
Yes – if adequate randomisation procedures are described, No
– if inadequate randomisation procedures are described,
Unclear – if the method of allocation to groups is not described
(a description of 'random' or 'randomised' is insufficient), N/A – if
only 1 index test was evaluated or all participants received all
tests
For C)
Yes – if appropriate methods of allocation concealment are
described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method of
allocation concealment is not described (sufficient detail to allow
a definite judgement is required), N/A – if only 1 index test was
evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within-person comparative
studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4)3.
'Unclear':
For non-comparative and within-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Are the included participants and chosen study
setting appropriate to answer the review question, i.e.
are the study results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in
Risk of Bias above), but is asking whether the chosen
study participants and setting are appropriate to answer
our review question.
 
A) For studies that will contribute to the analysis of participants
with suspected melanoma
Yes – if study participants appear to be representative of those
who might be referred for further investigation. Studies focussing
on participant populations with equivocal findings on clinical and/or
dermoscopic investigation are considered representative of those
who could receive OCT in practice.
No – if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features,
presence of differential diagnosis or co-morbidity, setting of the
study, and previous testing protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of participants
with suspected keratinocyte cancers
Yes – if study participants appear to be representative of those
who might be referred for further investigation. Studies focussing
on participant populations with equivocal findings on clinical and/or
dermoscopic investigation are considered representative of those
who could receive OCT in practice.
No – if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features,
presence of differential diagnosis or co-morbidity, setting of the
study, and previous testing protocols
Unclear – if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included lesions and
number of included participants is less than 5%
No – if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not
match the review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result
interpreted without knowledge of the results of the
reference standard?
Yes – if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
2) Was the diagnostic threshold at which the test was
considered positive (i.e. Melanoma, BCC or cSCC
present) prespecified?
Yes – if threshold was prespecified (i.e. prior to analysing study
results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic threshold
was prespecified
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
3) For within-person comparisons of index tests or
testing strategies (i.e. > 1 index test applied per
participant): was each index test result interpreted
without knowledge of the results of other index tests or
testing strategies?
Yes – if all index tests were described as interpreted without
knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test
have introduced bias?
For non-comparative and between-person comparison
studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), and 3) for any index1.
test 'Yes':
If answers to any 1 of questions 1), 2), or 3) for any2.
index test 'No':
If answers to any 1 of questions 1), 2), or 3) for any3.
index test 'Unclear':
 
For non-comparative and between-person comparison studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Was the test applied and interpreted in a clinically
applicable manner?
Yes – if a single clinician interpreted the scan with the participant
present, and made the diagnosis alone
No – If the accuracy 2x2 data are based on an average of multiple
observers, or consensus across observers; OR if the scan was
interpreted using the image alone, as opposed to with the
participant present.
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in
sufficient detail to allow replication?
Study results can only be reproduced if the diagnostic
threshold is described in sufficient detail. This item
applies equally to studies using pattern recognition and
those using checklists or algorithms to aid test
interpretation
Yes – if the criteria for diagnosis of Melanoma, BCC or cSCC were
reported in sufficient detail to allow replication
No – if the criteria for diagnosis of Melanoma, BCC or cSCC were
not reported in sufficient detail to allow replication
Unclear – if some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an
experienced examiner?
Yes – if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in the
use of the test
No – if the test was not interpreted by an experienced examiner
(see above)
Unclear – if the experience of the examiner(s) was not reported in
sufficient detail to judge or if examiners described as 'Expert' with
no further detail given
N/A – if system-based diagnosis, i.e. no observer interpretation
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Is there concern that the index test, its conduct, or
interpretation differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) - RISK OF BIAS
 
1) Is the reference standard likely to correctly classify
the target condition?
A) Disease-positive - 1 or more of the following:
histological confirmation of Melanoma, BCC or cSCC
following biopsy or lesion excision
clinical follow-up of benign-appearing lesions for at
least 6 (or 3 for cSCC) months following the
application of the index test, leading to a histological
diagnosis of BCC or cSCC
B) Disease-negative - 1 or more of the following:
histological confirmation of absence of Melanoma,
BCC or cSCC following biopsy or lesion excision in at
least 80% of disease-negative participants
clinical follow-up of benign-appearing lesions for a
minimum of 6 months (or 3 for cSCC) following the
index test in up to 20% of disease-negative
participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of Melanoma, BCC or
cSCC underwent 1 of the listed reference standards
No – if a final diagnosis of Melanoma, BCC or cSCC for any
participant was reached without histopathology
Unclear – if the method of final diagnosis was not reported for any
participant with a final diagnosis of BCC or cSCC or if the length of
clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a participant-
based analysis and it was not possible to determine whether the
detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test
B) Disease-negative
Yes – if at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up for a
minimum of 6 (or 3) months following the index test
No – if more than 20% of benign diagnoses were reached by
clinical follow-up for a minimum of 6 (or 3) months following the
index test or if clinical follow-up period was less than 6 (or 3)
months
Unclear – if the method of final diagnosis was not reported for any
participant with benign diagnosis
 
2) Were the reference standard results interpreted
without knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual
inspection or dermoscopy or both). We will deal with this
by not including the response to this item in the 'Risk of
bias' assessment for these tests. For reviews of all other
tests, this item will be retained
Yes – if the reference standard diagnosis was reached blinded to
the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not clearly
reported
 
Could the reference standard, its conduct, or its
interpretation have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Expert opinion (with no histological confirmation) was
not used as a reference standard
'Expert opinion' means diagnosis based on the standard
clinical examination, with no histology or lesion follow-up
Yes – if expert opinion was not used as a reference standard for
any participant
No – if expert opinion was used as a reference standard for any
participant
Unclear – if not clearly reported
2) Was histology interpretation carried out by an
experienced histopathologist or by a
dermatopathologist?
Yes – if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No – if histology interpretation was reported to be carried out by a
less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist were
not reported
 
Is there concern that the target condition as defined by
the reference standard does not match the review
question?
If answers to all questions 1) and 2) 'Yes':1.
If answers to either question 1) or 2) 'No':2.
If answers to either question 1) or 2)3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
 
1) Was there an appropriate interval between index test
and reference standard?
A) For histopathological reference standard, was the
interval between index test and reference standard ≤ 1
month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least
6 (or 3) months' follow-up following application of index
test(s) for studies of Melanoma, BCC (or cSCC)?
 
A)
Yes – if study reports ≤ 1 month between index and reference
standard
No – if study reports > 1 month between index and reference
standard
Unclear – if study does not report interval between index and
reference standard
B)
Yes – if study reports ≥ 6 (or 3 for cSCC) months' follow-up
No – if study reports < 6 (or 3 for cSCC) months' follow-up
Unclear – if study does not report length of clinical follow-up
2) Did all participants receive the same reference
standard?
Yes – if all participants underwent the same reference standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1
month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report interval between index tests
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison
studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) is3.
'Unclear':
For non-comparative and between-person comparison studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
5 Summary of included study details
Study
author
Outcomes
reported
Study
type Incl criteria No_patientsLesion_site
Test
Machine
Resolution
Tissue
penetration
Centre
wavelength
Threshold Diagnosticmethod
Observer
qualifications (n)
Test experience
Test
failures
Reference
standard
Final
diagnoses Prevalence
Melanoma
Gambichler
2014
MM alone
MM+MiS
NC
P-CS
Ger
MSL for
excision
Excluded:
Frank
ulceration,
marked
hyperkeratosis
64 / 93 Any (notdescribed)
HD–OCT
Skintell HD-
OCT (Agfa,
Belgium)
axial 5μm,
lateral 3μm
570μm
1300nm
Score ≥ -1 MM;
score of ≥ -1.5
benign MSL
based on sum
of sub-scores
for various
OCT
characteristics
Image-based
Blinded to
VI/Derm
NR (n = 1)
"experienced" NR Histology
MM 25;
MiS 2;
BN 64
27%
Wessels
2015
MM+MiS
NC
P-CS
NL
PSL
scheduled for
excision,
identified
during routine
skin cancer
screening (all
clinically
suspicious for
melanoma; 14
with
dermoscopic
suspicion)
Excluded:
none reported
33 / 40
Trunk and
Neck (28,
70%),
arms and
legs (12,
30%)
OCT (Swept
source)
Santec
Inner Vision
2000
axial
10μm,
lateral
20μm
2000μm
1300nm
Attenuation
coefficient
5.4mm-1
(Data on
morphological
characteristics
excluded)
Image-based
Blinding NR
NR (n = 1)
NR NR Histology
MM 7;
MiS 2;
BN 31
23%
BCC
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Study
author
Outcomes
reported
Study
type Incl criteria No_patientsLesion_site
Test
Machine
Resolution
Tissue
penetration
Centre
wavelength
Threshold Diagnosticmethod
Observer
qualifications (n)
Test experience
Test
failures
Reference
standard
Final
diagnoses Prevalence
Markowitz
2015
BCC
WPC
P-CS
US
Pink lesions
suspicious for
BCC and
clinically
challenging
(head/neck
only);
requiring
biopsy for
confirmation
of diagnosis,
and eligible for
Mohs surgery
Excluded:
History or
evidence
mets, topical
actinic therapy
within 8wks
prior to eval,
other skin
conditions
within lesion
100 / 115
Head/Neck
(not further
described)
OCT (Swept
source)
VivoSight
OCT
Also reports
in person
diagnosis
for VI and
for
Dermoscopy
axial
10μm,
lateral
7.5μm
2000μm
1300nm
Diagnostic
judgement
(BCC
present/absent)
Image-based
(unclear if
VI/dermoscopy
images
provided)
NR (n = NR)
NR NR
Histology
(biopsy)
BCC 70;
Other 45
(not
described)
61%
Ulrich 2015
BCC
WPC
P-CS
Ger
Non-
pigmented
pink lesions
with clinical
suspicion of
BCC;
requiring
biopsy for
diagnostic
confirmation
Excluded:
Typical clinical
appearance
BCC, PSL,
unstable or
uncontrolled
clinically
significant
medical
conditions
164 / 256
Head
(41%),
Upper
body
(48.8%),
Other
(0.2%)
OCT (Swept
source)
VivoSight
OCT
Also reports
in person
diagnosis
for VI and
for
Dermoscopy
axial
10μm,
lateral
7.5μm
2000μm
1300nm
Diagnostic
judgement
(BCC
present/absent)
In person
(following
VI/Derm)
NR (n = NR)
"regular users"; >=
3mos experience
NR
Histology
(biopsy or
excision)
BCC 141;
SK 6;
AK 32;
BD 17;
Other 40
60%
Wahrlich
2015
BCC
NC
CCS
Ger
Selected
participants
with BCC,
cSCC, BD, AK
based on prior
clinical
examination
and
dermatoscopy
Excluded:
ulcerated
50 / 50 NR
OCT (Swept
source)
VivoSight
OCT
axial
10μm,
lateral
7.5μm
2000μm
1300nm
1. Berlin score
≥ 8
2. Berlin score
≥12
Image-based
(reviewed
following
histopathology)
Dermatopathologist
(n = 1)
"familiar with OCT"
NR Histology
BCC 29;
cSCC 9
AK 5; BD
7
58%
cSCC
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Study
author
Outcomes
reported
Study
type Incl criteria No_patientsLesion_site
Test
Machine
Resolution
Tissue
penetration
Centre
wavelength
Threshold Diagnosticmethod
Observer
qualifications (n)
Test experience
Test
failures
Reference
standard
Final
diagnoses Prevalence
Wahrlich
2015
cSCC
NC
CCS
Ger
Selected
participants
with BCC,
cSCC, BD, AK
based on prior
clinical
examination
and
dermatoscopy
Excluded:
ulcerated
50 / 50 NR
OCT (Swept
source)
VivoSight
OCT
axial
10μm,
lateral
7.5μm
2000μm
1300nm
1. Berlin score
≥ 8
2. Berlin score
≥12
Image-based
(reviewed
following
histopathology)
Dermatopathologist
(n = 1)
"familiar with OCT"
NR Histology
BCC 29;
cSCC 9
AK 5; BD
7
18%
Footnotes: AK - actinic keratosis; BCC - basal cell carcinoma; ?BCC - possible basal cell carcinoma; BD - Bowens disease;
BN - benign naevus; CCS - case-control study; cSCC - cutnaeous squamous cell carcinoma; Derm - dermatoscopy; Ger -
Germany; HD - high definition; H/N - Head and neck; LED - disease type, acronym not provided by study; Mis - melanoma in
situ; MM - malignant melanoma; MSL - melanocytic skin lesion; NC - non-comparative study design; NR - not reported; NR-
CS - case series data collection method not reported; NS - not specified; OCT - optical coherence tomography; P-CS -
prospective case series; PSL - pigmented skin lesion; R-CS - restrospective case series; SK - seborrhoeic keratosis; US -
United States of America; VI - visual inspection; WPC - within-person comparison study design.
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